<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>525</serviceExecutionTime><Drug id="63012"><DrugName>ceftolozane sulfate + tazobactam sodium (bacterial infection), Cubist</DrugName><DrugNamesKey><Name id="43045088">Zerbaxa</Name></DrugNamesKey><DrugSynonyms><Name><Value>CXA-101 + tazobactam (bacterial infection), Calixa</Value></Name><Name><Value>CXA-101 + tazobactam</Value></Name><Name><Value>CXA-101 + tazobactam (bacterial infection), Cubist</Value></Name><Name><Value>CXA/TAZ</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>ceftolozane sulfate + tazobactam</Value></Name><Name><Value>CXA-201</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Zerbaxa</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>ceftolozane sulfate + tazobactam sodium</Value></Name><Name><Value>ceftolozane sulfate + tazobactam sodium (bacterial infection), Cubist</Value></Name><Name><Value>MK-7625A</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>689293-68-3</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>89786-04-9</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1013295">Astellas Pharma Inc</CompanyOriginator><CompaniesPrimary><Company id="18077">Merck &amp; Co Inc</Company></CompaniesPrimary><CompaniesSecondary><Company id="1013295">Astellas Pharma Inc</Company><Company id="1046343">Calixa Therapeutics Inc</Company><Company id="21697">Cubist Pharmaceuticals Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="63012" type="Drug"><TargetEntity id="655761" type="siDrug">Ceftolozane sulfate/tazobactam</TargetEntity></SourceEntity><SourceEntity id="1013295" type="Company"><TargetEntity id="4295876965" type="organizationId">Astellas Pharma Inc</TargetEntity></SourceEntity><SourceEntity id="1046343" type="Company"><TargetEntity id="4297909978" type="organizationId">Calixa Therapeutics Inc</TargetEntity></SourceEntity><SourceEntity id="18077" type="Company"><TargetEntity id="4295904886" type="organizationId">Merck &amp; Co Inc</TargetEntity></SourceEntity><SourceEntity id="21697" type="Company"><TargetEntity id="4295906092" type="organizationId">Cubist Pharmaceuticals LLC</TargetEntity></SourceEntity><SourceEntity id="116" type="ciIndication"><TargetEntity id="10051910" type="MEDDRA"/></SourceEntity><SourceEntity id="120" type="ciIndication"><TargetEntity id="D004927" type="MeSH"/><TargetEntity id="-1969770508" type="omicsDisease"/><TargetEntity id="803" type="siCondition"/></SourceEntity><SourceEntity id="137" type="ciIndication"><TargetEntity id="D016905" type="MeSH"/><TargetEntity id="-409642348" type="omicsDisease"/><TargetEntity id="801" type="siCondition"/></SourceEntity><SourceEntity id="1434" type="ciIndication"><TargetEntity id="10051904" type="MEDDRA"/></SourceEntity><SourceEntity id="1438" type="ciIndication"><TargetEntity id="10061470" type="MEDDRA"/><TargetEntity id="D011512" type="MeSH"/></SourceEntity><SourceEntity id="1815" type="ciIndication"><TargetEntity id="J15" type="ICD10"/><TargetEntity id="10060946" type="MEDDRA"/><TargetEntity id="D018410" type="MeSH"/><TargetEntity id="-2031977293" type="omicsDisease"/><TargetEntity id="928" type="siCondition"/></SourceEntity><SourceEntity id="195" type="ciIndication"><TargetEntity id="4198" type="siCondition"/></SourceEntity><SourceEntity id="2019" type="ciIndication"><TargetEntity id="K81" type="ICD10"/><TargetEntity id="10008612" type="MEDDRA"/><TargetEntity id="D002764" type="MeSH"/><TargetEntity id="-1275543177" type="omicsDisease"/><TargetEntity id="437" type="siCondition"/></SourceEntity><SourceEntity id="280" type="ciIndication"><TargetEntity id="804" type="siCondition"/></SourceEntity><SourceEntity id="284" type="ciIndication"><TargetEntity id="10037596" type="MEDDRA"/><TargetEntity id="D011704" type="MeSH"/><TargetEntity id="-721934222" type="omicsDisease"/><TargetEntity id="344" type="siCondition"/></SourceEntity><SourceEntity id="2994" type="ciIndication"><TargetEntity id="K75.0" type="ICD10"/><TargetEntity id="10024652" type="MEDDRA"/><TargetEntity id="D008100" type="MeSH"/><TargetEntity id="-54106460" type="omicsDisease"/><TargetEntity id="3159" type="siCondition"/></SourceEntity><SourceEntity id="3082" type="ciIndication"><TargetEntity id="10060921" type="MEDDRA"/><TargetEntity id="D018784" type="MeSH"/><TargetEntity id="-1959458454" type="omicsDisease"/><TargetEntity id="871" type="siCondition"/></SourceEntity><SourceEntity id="312" type="ciIndication"><TargetEntity id="10061372" type="MEDDRA"/><TargetEntity id="D013290" type="MeSH"/><TargetEntity id="-669221578" type="omicsDisease"/><TargetEntity id="814" type="siCondition"/></SourceEntity><SourceEntity id="3269" type="ciIndication"><TargetEntity id="4172" type="siCondition"/></SourceEntity><SourceEntity id="3317" type="ciIndication"><TargetEntity id="4173" type="siCondition"/></SourceEntity><SourceEntity id="403" type="ciIndication"><TargetEntity id="N30" type="ICD10"/><TargetEntity id="10011781" type="MEDDRA"/><TargetEntity id="D003556" type="MeSH"/><TargetEntity id="-1776447469" type="omicsDisease"/><TargetEntity id="941" type="siCondition"/></SourceEntity><SourceEntity id="452" type="ciIndication"><TargetEntity id="K65" type="ICD10"/><TargetEntity id="10034674" type="MEDDRA"/><TargetEntity id="D010538" type="MeSH"/><TargetEntity id="-1837137483" type="omicsDisease"/><TargetEntity id="2483" type="siCondition"/></SourceEntity><SourceEntity id="456" type="ciIndication"><TargetEntity id="4196" type="siCondition"/></SourceEntity><SourceEntity id="598" type="ciIndication"><TargetEntity id="D004756" type="MeSH"/><TargetEntity id="-1005348715" type="omicsDisease"/><TargetEntity id="1580" type="siCondition"/></SourceEntity><SourceEntity id="638" type="ciIndication"><TargetEntity id="10061259" type="MEDDRA"/><TargetEntity id="D007710" type="MeSH"/><TargetEntity id="-801568713" type="omicsDisease"/><TargetEntity id="4174" type="siCondition"/></SourceEntity><SourceEntity id="1594" type="Action"><TargetEntity id="5306" type="Mechanism">Drugs Targeting Mycobacterium tuberculosis Proteins</TargetEntity><TargetEntity id="3697" type="Mechanism">Drugs Targeting Escherichia coli Proteins</TargetEntity><TargetEntity id="4563" type="Mechanism">Anti-Diphteria Toxin (Corynebacterium diphtheriae)</TargetEntity><TargetEntity id="1060" type="Mechanism">Efflux Pump (Bacterial) Inhibitors</TargetEntity><TargetEntity id="5353" type="Mechanism">Drugs Targeting Clostridium tetani Proteins</TargetEntity><TargetEntity id="5053" type="Mechanism">Anti-Diphtheria Toxin</TargetEntity><TargetEntity id="2409" type="Mechanism">Carbon Monoxide-Releasing Agents</TargetEntity><TargetEntity id="3878" type="Mechanism">Drugs Targeting Bacterial Chaperones</TargetEntity><TargetEntity id="3994" type="Mechanism">Drugs Targeting Pseudomonas aeruginosa Proteins</TargetEntity><TargetEntity id="4457" type="Mechanism">Drugs Targeting Staphylococcus aureus Proteins</TargetEntity><TargetEntity id="4493" type="Mechanism">Drugs Targeting Campylobacter jejuni Proteins</TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity></SourceEntity><SourceEntity id="86" type="Action"><TargetEntity id="501" type="Mechanism">beta-Lactamase Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Abdominal abscess - US - Feb-2015</FirstLaunched><FirstLaunched>Bacteroides fragilis infection - US - Feb-2015</FirstLaunched><FirstLaunched>Complicated urinary tract infection - US - Feb-2015</FirstLaunched><FirstLaunched>Enterobacter cloacae infection - US - Feb-2015</FirstLaunched><FirstLaunched>Gram negative bacterium infection - US - Feb-2015</FirstLaunched><FirstLaunched>Klebsiella oxytoca infection - US - Feb-2015</FirstLaunched><FirstLaunched>Proteus mirabilis infection - US - Feb-2015</FirstLaunched><FirstLaunched>Pseudomonas aeruginosa infection - US - Feb-2015</FirstLaunched><FirstLaunched>Streptococcus anginosus infection - US - Feb-2015</FirstLaunched><FirstLaunched>Streptococcus constellatus infection - US - Feb-2015</FirstLaunched></PhaseHighestDetailed><RegulatoryDesignations><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><RegulatoryDesignation id="11">Priority Review</RegulatoryDesignation><RegulatoryDesignation id="12">Qualified Infectious Disease Product</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="116">Enterobacter infection</Indication><Indication id="120">Escherichia coli infection</Indication><Indication id="137">Gram negative bacterium infection</Indication><Indication id="1394">Bacteroides fragilis infection</Indication><Indication id="1434">Citrobacter infection</Indication><Indication id="1438">Proteus infection</Indication><Indication id="1815">Bacterial pneumonia</Indication><Indication id="195">Klebsiella pneumoniae infection</Indication><Indication id="2019">Cholecystitis</Indication><Indication id="280">Pseudomonas aeruginosa infection</Indication><Indication id="284">Pyelonephritis</Indication><Indication id="2994">Liver abscess</Indication><Indication id="3082">Abdominal abscess</Indication><Indication id="312">Streptococcus infection</Indication><Indication id="3269">Enterobacter cloacae infection</Indication><Indication id="3317">Klebsiella oxytoca infection</Indication><Indication id="3334">Streptococcus anginosus infection</Indication><Indication id="3335">Streptococcus constellatus infection</Indication><Indication id="3898">Complicated urinary tract infection</Indication><Indication id="403">Cystitis</Indication><Indication id="452">Peritonitis</Indication><Indication id="456">Proteus mirabilis infection</Indication><Indication id="598">Enterobacteriaceae infection</Indication><Indication id="638">Klebsiella infection</Indication></IndicationsPrimary><ActionsPrimary><Action id="86">Beta lactamase inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="1537">Cephalosporin</Action><Action id="1594">Antibacterial</Action><Action id="2953">Anti-inflammatory</Action><Action id="7293">Synergist</Action></ActionsSecondary><Technologies><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="898">Formulation powder</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="66">Antibiotic</Technology><Technology id="175">Drug combination</Technology></Technologies><EphmraCodes><Ephmra><Code>J1</Code><Name>SYSTEMIC ANTIBACTERIALS</Name></Ephmra><Ephmra><Code>J1D</Code><Name>CEPHALOSPORINS</Name></Ephmra></EphmraCodes><LastModificationDate>2019-07-02T13:17:41.000Z</LastModificationDate><ChangeDateLast>2019-07-03T00:00:00.000Z</ChangeDateLast><AddedDate>2009-03-30T10:45:44.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="18077" linkType="Company"&gt;Merck&lt;/ulink&gt;, following its acquisition of &lt;ulink linkID="21697" linkType="Company"&gt;Cubist Pharmaceuticals&lt;/ulink&gt; (and following Cubist's acquisition of &lt;ulink linkID="1046343" linkType="Company"&gt;Calixa Therapeutics&lt;/ulink&gt;, which had acquired rights from &lt;ulink linkID="1013295" linkType="Company"&gt;Astellas Pharma&lt;/ulink&gt;), has developed and launched CXA-201 (MK-7625A; CXA/TAZ; Zerbaxa),  an iv combination of  the cephalosporin  &lt;ulink linkID="21303" linkType="Drug"&gt;ceftolozane sulfate&lt;/ulink&gt; (CXA-101) and the   beta-lactamase inhibitor tazobactam sodium [&lt;ulink linkID="1930131" linkType="Reference"&gt;1930131&lt;/ulink&gt;].   In the US, the product is indicated in patients 18 years or older for the treatment of the following infections caused by designated susceptible microorganisms - complicated Intra-abdominal Infections (cIAI), used in combination with metronidazole; complicated urinary tract infections (cUTI), including pyelonephritis; and hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) - to reduce the development of drug-resistant bacteria and maintain the effectiveness of Zerbaxa and other antibacterial drugs  [&lt;ulink linkID="1622503" linkType="Reference"&gt;1622503&lt;/ulink&gt;]. In the EU, the product is indicated in adults for the treatment of cIAI, acute pyelonephritis and cUTI (designated susceptible microorganisms: E cloacae, E coli, K oxytoca, K pneumoniae, P mirabilis, P aeruginosa, S anginosus, S constellatus and S salivarius) [&lt;ulink linkID="1728094" linkType="Reference"&gt;1728094&lt;/ulink&gt;]. In Japan, the drug is indicated for the treatment  of cUTI, cystitis, pyelonephritis, peritonitis, intraabdominal abscess, cholecystitis, and liver abscess (designated susceptible microorganisms: Streptococcus spp, Enterobacteriaceae spp, including E coli, Citrobacter spp, Klebsiella spp, Enterobacter spp and Proteus spp, and P aeruginosa) [&lt;ulink linkID="2113240" linkType="Reference"&gt;2113240&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2015, the drug was to be launched 'immediately' in the US by Merck for cUTI and cIAI caused by designated susceptible Gram-negative bacteria [&lt;ulink linkID="1631301" linkType="Reference"&gt;1631301&lt;/ulink&gt;]. In 2016, the product was launched in the EU [&lt;ulink linkID="1904530" linkType="Reference"&gt;1904530&lt;/ulink&gt;]. In June 2019, the drug was launch in Japan for the treatment  of cUTI, cystitis, pyelonephritis, peritonitis, intraabdominal abscess, cholecystitis, and liver abscess [&lt;ulink linkID="2168816" linkType="Reference"&gt;2168816&lt;/ulink&gt;].    &lt;/para&gt;&lt;para&gt;In June 2019, the FDA approved an sNDA under Priority Review for HABP/VABP [&lt;ulink linkID="2158811" linkType="Reference"&gt;2158811&lt;/ulink&gt;], [&lt;ulink linkID="2158603" linkType="Reference"&gt;2158603&lt;/ulink&gt;]. By February 2019, a filing for CXA-201 for nosocomial pneumonia, including VABP caused by certain susceptible Gram-negative microorganisms, based on the ASPECT-NP trial, had been submitted to the EMA and was under review [&lt;ulink linkID="2117044" linkType="Reference"&gt;2117044&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;Cubist owns the rights to &lt;ulink linkID="PA3301926" linkType="Patent"&gt;EP-01556389&lt;/ulink&gt; B1 (expires December 2023) and &lt;ulink linkID="PA2976328" linkType="Patent"&gt;US-07129232&lt;/ulink&gt; (expires October 2024) covering the drug [&lt;ulink linkID="1288227" linkType="Reference"&gt;1288227&lt;/ulink&gt;]. In February 2015, Merck noted that the US patent covering the drug is stated to expire in 2028 subject to a pending patent term restoration [&lt;ulink linkID="1642667" linkType="Reference"&gt;1642667&lt;/ulink&gt;]; in February 2016, the company also noted that the patent was eligible for a 6-month pediatric exclusivity period [&lt;ulink linkID="1743025" linkType="Reference"&gt;1743025&lt;/ulink&gt;]. In February 2017, Merck stated that in major EU markets, including France, Germany, Italy, Spain and the  UK, patent protection would expire in 2023, and in some of these countries SPCs have been granted expiring in 2028 with eligibility for 6 months pediatric exclusivity [&lt;ulink linkID="1904530" linkType="Reference"&gt;1904530&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In September 2018, an sNDA was planned in the US for HABP and VABP based on data from the pivotal ASPECT-NP trial  [&lt;ulink linkID="2071416" linkType="Reference"&gt;2071416&lt;/ulink&gt;]. In February 2019, the FDA accepted for Priority Review an sNDA for CXA-201 for the treatment of adult patients with nosocomial pneumonia, including VABP caused by certain susceptible Gram-negative microorganisms, based on the ASPECT-NP trial. At that time, the target PDUFA date was set for June 03, 2019 [&lt;ulink linkID="2117044" linkType="Reference"&gt;2117044&lt;/ulink&gt;]. In June 2019, the sNDA was approved for adult patients with HABP/VABP caused by designated susceptible Gram-negative microorganisms (Enterobacter cloacae, Escherichia coli, Haemophilus influenzae, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Serratia marcescens) [&lt;ulink linkID="2158603" linkType="Reference"&gt;2158603&lt;/ulink&gt;], [&lt;ulink linkID="2158811" linkType="Reference"&gt;2158811&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In April 2014, Cubist filed for US approval of the drug for cUTI and cIAI [&lt;ulink linkID="1548828" linkType="Reference"&gt;1548828&lt;/ulink&gt;]. In June 2014, the FDA accepted the NDA with Priority Review and a PDUFA  date of December 21, 2014 [&lt;ulink linkID="1571561" linkType="Reference"&gt;1571561&lt;/ulink&gt;]. In December 2014, the FDA approved the drug for cUTI and cIAI caused by designated susceptible Gram-negative bacteria [&lt;ulink linkID="1622359" linkType="Reference"&gt;1622359&lt;/ulink&gt;]. In February 2015, the drug was to be launched 'immediately' by Merck &amp;amp; Co [&lt;ulink linkID="1631301" linkType="Reference"&gt;1631301&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In October 2012, Cubist submitted an application for Qualified Infectious Disease Product (QIDP) Designation to the FDA under the Generating Antibiotic Incentives Now act, for a five- year extension of Hatch-Waxman exclusivity, priority review and eligibility for fast-track status [&lt;ulink linkID="1333041" linkType="Reference"&gt;1333041&lt;/ulink&gt;]; in December 2012, the FDA granted  QIDP designation for cIAI [&lt;ulink linkID="1348383" linkType="Reference"&gt;1348383&lt;/ulink&gt;]. In February 2013, the FDA also granted QIDP designation to the product for HABP/VABP and cUTI, and granted Fast Track status for cIAI   [&lt;ulink linkID="1387641" linkType="Reference"&gt;1387641&lt;/ulink&gt;]. In May 2013, the FDA granted Fast Track status for HABP/VABP and cUTI [&lt;ulink linkID="1416427" linkType="Reference"&gt;1416427&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In April 2014, an MAA for cUTI and cIAI was to be filed in 2H14 [&lt;ulink linkID="1548828" linkType="Reference"&gt;1548828&lt;/ulink&gt;]. In August 2014, the EMA accepted for review an MAA for both indications, and a decision was expected during 2H15 [&lt;ulink linkID="1587108" linkType="Reference"&gt;1587108&lt;/ulink&gt;]. In July 2015, the EMA's CHMP recommended approval of the antibiotic for the treatment of cIAI, acute pyelonephritis and cUTI [&lt;ulink linkID="1680288" linkType="Reference"&gt;1680288&lt;/ulink&gt;], [&lt;ulink linkID="1680605" linkType="Reference"&gt;1680605&lt;/ulink&gt;]. In September 2015, the EMA approved Zerbaxa for the treatment of adults with complicated bacterial infections, specifically cIAI, cUTI and pyelonephritis [&lt;ulink linkID="1699848" linkType="Reference"&gt;1699848&lt;/ulink&gt;]. In 2016, the product was launched in the EU [&lt;ulink linkID="1904530" linkType="Reference"&gt;1904530&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2012, Cubist planned to file for marketing approval for  nosocomial pneumonia  in the EU [&lt;ulink linkID="1319878" linkType="Reference"&gt;1319878&lt;/ulink&gt;]. In February 2013, Cubist expected launch for nosocomial pneumonia and VABP in 2019 [&lt;ulink linkID="1392842" linkType="Reference"&gt;1392842&lt;/ulink&gt;]. In September 2018, an MAA was planned in the EU seeking   approval for HABP and VABP based on data from the pivotal ASPECT-NP trial  [&lt;ulink linkID="2071416" linkType="Reference"&gt;2071416&lt;/ulink&gt;]. By February 2019, a filing for CXA-201 for the treatment of adult patients with nosocomial pneumonia, including VABP caused by certain susceptible Gram-negative microorganisms, based on the ASPECT-NP trial, had been submitted to the EMA and was under review [&lt;ulink linkID="2117044" linkType="Reference"&gt;2117044&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Japan&lt;/subtitle&gt;In February 2018, MSD filed an application for approval in Japan for the treatment of IAI and UTI due to streptococcus, E coli, citrobacter, klebsiella, enterobacter, proteus, P aeruginosa and bacteroides [&lt;ulink linkID="2009226" linkType="Reference"&gt;2009226&lt;/ulink&gt;]. In November 2018, the Second Committee on New Drugs PAFSC  discussed the filing and recommended the approval. At that time, a decision on approval was expected by the end of 2018 [&lt;ulink linkID="2102880" linkType="Reference"&gt;2102880&lt;/ulink&gt;]. In January 2019, the drug was approved in Japan for the treatment  of cystitis, pyelonephritis, peritonitis, intraabdominal abscess, cholecystitis, and liver abscess [&lt;ulink linkID="2109713" linkType="Reference"&gt;2109713&lt;/ulink&gt;]. In June 2019, the drug was launch in Japan in that setting [&lt;ulink linkID="2168816" linkType="Reference"&gt;2168816&lt;/ulink&gt;].   &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the world&lt;/subtitle&gt;&lt;subtitle&gt;Canada&lt;/subtitle&gt;In September 2015, the product was approved in Canada, as Zerbaxa, for the treatment of cIAI, in combination with metronidazole, and cUTI including pyelonephritis, caused by designated microorganisms  [&lt;ulink linkID="1708728" linkType="Reference"&gt;1708728&lt;/ulink&gt;], [&lt;ulink linkID="1720241" linkType="Reference"&gt;1720241&lt;/ulink&gt;]. In February 2016, the antibiotic was launched in Canada [&lt;ulink linkID="1736638" linkType="Reference"&gt;1736638&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Latin America&lt;/subtitle&gt;In March 2017, the product was approved in Argentina  for the treatment of cIAIs,  pyelonephritis  and  cUTIs [&lt;ulink linkID="2077517" linkType="Reference"&gt;2077517&lt;/ulink&gt;]; launch was presumed to have occurred shortly after.&lt;/para&gt;&lt;para&gt;By August 2016, the product had been filed for approval in Mexico [&lt;ulink linkID="2077585" linkType="Reference"&gt;2077585&lt;/ulink&gt;]. By April 2017, approval had been granted in Mexico, presumably for the treatment of cIAIs,  pyelonephritis  and  cUTIs [&lt;ulink linkID="2077586" linkType="Reference"&gt;2077586&lt;/ulink&gt;]; launch was presumed to have occurred shortly after.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Middle East and Africa&lt;/subtitle&gt;In July 2016, the product was filed for approval in Israel. In February 2018, the product was approved for the treatment of cIAIs, acute pyelonephritis caused by pathogens resistant to other treatments as confirmed by urine culture, and  cUTIs [&lt;ulink linkID="2077552" linkType="Reference"&gt;2077552&lt;/ulink&gt;]; launch was presumed to have occurred shortly after. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Asia Pacific&lt;/subtitle&gt;By January 2018, the combination had been approved for the treatment of cUTI in Taiwan caused by E Coli, Klebsiella pneumoniae, Proteus mirabilis, and P aeruginosa [&lt;ulink linkID="2077654" linkType="Reference"&gt;2077654&lt;/ulink&gt;]; launch was presumed to have occurred shortly after. &lt;/para&gt;&lt;para&gt;In April 2017, the combination was approved in Korea [&lt;ulink linkID="1929846" linkType="Reference"&gt;1929846&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2015, the product was approved in Australia as Zerbaxa, for the treatment of cIAI in combination with metronidazole, and cUTI including pyelonephritis, caused by designated microorganisms  [&lt;ulink linkID="1736269" linkType="Reference"&gt;1736269&lt;/ulink&gt;], [&lt;ulink linkID="1834854" linkType="Reference"&gt;1834854&lt;/ulink&gt;]. By November 2017, the drug had been launched in Australia [&lt;ulink linkID="2124690" linkType="Reference"&gt;2124690&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Postmarketing><displayLabel>Postmarketing</displayLabel><value>&lt;Postmarketing&gt;&lt;para&gt;In October 2017, clinical data from a real world, retrospective, one center study (conducted in Nevada), which evaluated the real world efficacy of ceftolozane/tazobactam in patients with Gram-negative pathogen-associated infections were presented at 2017 IDWeek in San Diego, CA. Patients who were admitted to University Medical Center, Las Vegas between 07/01/2015 to 02/28/2017 and received ceftolozane/tazobactam for &amp;gt; 48 h were included in the study. A total of seven patients received empiric ceftolozane/tazobactam therapy. A patient required escalation of therapy after ceftolozane/tazobactam. The average duration of ceftolozane/tazobactam treatment was 10 days. Successful clinical outcome was achieved in a total of 24 ceftolozane/tazobactam treated patients, and documented microbiological eradication was observed in 12/13 patients. Infection related death occurred in three patients [&lt;ulink linkID="1968047" linkType="Reference"&gt;1968047&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2015, a prospective, multicenter, open-label, single group assignment, phase IV trial (&lt;ulink linkID="227255" linkType="Protocol"&gt;NCT02421120&lt;/ulink&gt;; HHC-2015-0107) was scheduled to begin in June 2015 in the US, in patients (expected n = 20) with P aeruginosa infection, to assess the safety and pharmacokinetics of  CXA-101. At that time, the trial was expected to complete in August 2016 [&lt;ulink linkID="1653758" linkType="Reference"&gt;1653758&lt;/ulink&gt;].&lt;/para&gt;&lt;/Postmarketing&gt;</value></Postmarketing><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Nosocomial pneumonia&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In September 2014, a randomized, double-blind, multicenter, phase III trial (&lt;ulink linkID="174961" linkType="Protocol"&gt;NCT02070757&lt;/ulink&gt;; CXA-NP-11-04; ASPECT-NP) was initiated in the US and Europe to evaluate the safety and efficacy of CXA-201 in adult patients (n = 726, Taiwanese  n = 19) with  VABP/HABP. At that time, the trial was expected to complete in February 2018  [&lt;ulink linkID="1623745" linkType="Reference"&gt;1623745&lt;/ulink&gt;], [&lt;ulink linkID="1623746" linkType="Reference"&gt;1623746&lt;/ulink&gt;]. In  June 2018, the trial completed [&lt;ulink linkID="1623745" linkType="Reference"&gt;1623745&lt;/ulink&gt;].  In September 2018, results were reported from the pivotal trial  showing that  it met  its primary endpoints  by demonstrating non-inferiority to &lt;ulink linkID="3616" linkType="Drug"&gt;meropenem&lt;/ulink&gt; in day 28 all-cause mortality and in clinical cure rate at the test-of-cure visit  [&lt;ulink linkID="2071416" linkType="Reference"&gt;2071416&lt;/ulink&gt;]. In February 2019, data from the trial were expected to be presented in 2019 [&lt;ulink linkID="2116422" linkType="Reference"&gt;2116422&lt;/ulink&gt;]. In April 2019, further clinical results were presented at the 29th ECCMID in Amsterdam, Netherlands. In ceftolozane/tazobactam and meropenem groups, a 28-day all-cause mortality (primary endpoint) was reported in 24 and 25.3%, respectively, with weighted proportion difference of 1.1%. In ceftolozane/tazobactam and meropenem groups, clinical response at test-of-cure (TOC; 7 to 14 days after end of therapy) in the ITT population (key secondary endpoint) was reported in 54.4 and 53.3% of patients, respectively; and clinical cure at TOC in clinically evaluable (CE) population was 63.8 and 64.7%, respectively [&lt;ulink linkID="2140426" linkType="Reference"&gt;2140426&lt;/ulink&gt;], [&lt;ulink linkID="2141235" linkType="Reference"&gt;2141235&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2013, Cubist planned to conduct a phase III trial to evaluate the safety and efficacy of CXA-201 for HABP/VABP in 1H14 [&lt;ulink linkID="1502573" linkType="Reference"&gt;1502573&lt;/ulink&gt;]. In January 2014, the company stated that it had been in discussion with the FDA regarding the approach to HABP/VABP; it was in agreement with the agency that it would pursue a modified original protocol in HABP/VABP to take full advantage of the spectrum of the molecule, instead of limiting the approach to specific pathogens. The trial was to enroll 650 patients; at that time, the company expected to be in a position to make projections regarding trial completion  in mid-2015 once enrollment had occurred    [&lt;ulink linkID="1518567" linkType="Reference"&gt;1518567&lt;/ulink&gt;]. In April 2014, Cubist was initiating investigational sites for the  pivotal trial [&lt;ulink linkID="1548828" linkType="Reference"&gt;1548828&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2012, Cubist was planning an open-label, phase III trial for VABP using higher doses of CXA-201, with data expected in 2014 [&lt;ulink linkID="1333801" linkType="Reference"&gt;1333801&lt;/ulink&gt;]. In July 2013, the randomized  safety and efficacy trial was initiated [&lt;ulink linkID="1454221" linkType="Reference"&gt;1454221&lt;/ulink&gt;]. By January 2014, the open-label trial had been stopped in favor of executing the registrational  studies supporting it and &lt;ulink linkID="30819" linkType="Drug"&gt;tedizolid&lt;/ulink&gt;, as quickly as possible [&lt;ulink linkID="1518567" linkType="Reference"&gt;1518567&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In April 2013, a phase II, open-label trial was expected to start in mid-2013; at that time, data were expected in 2015 [&lt;ulink linkID="1407277" linkType="Reference"&gt;1407277&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2010, a phase II trial for nosocomial pneumonia was expected to begin in early 2011 [&lt;ulink linkID="1070204" linkType="Reference"&gt;1070204&lt;/ulink&gt;]. In September 2012, the drug was in phase II development [&lt;ulink linkID="1319878" linkType="Reference"&gt;1319878&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In  September 2015, results from a prospective, single-dose, parallel-group, phase I study examining the pharmacokinetics, safety and efficacy of ceftolozane + tazobactam in healthy Japanese (n = 10), Chinese (n = 9) and Caucasian (n = 10) subjects were presented at the 2015 ICAAC/ICC Meeting in San Diego, CA. Study subjects were treated with a single iv infusion of ceftolozane + tazobactam (1.5 g) for 1 h on day 1 and underwent a 48-h washout period and again received a single iv infusion of ceftolozane + tazobactam (3 g) for 1 h on day 4. Pharmacokinetics parameters of ceftolozane + tazobactam (Cmax, AUC0 to t and AUC0 to infinity) were approximately dose-proportional and comparable between Japanese, Chinese and Caucasian subjects. Ceftolozane + tazobactam was safe and exhibited good tolerability [&lt;ulink linkID="1693328" linkType="Reference"&gt;1693328&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2012, data from a multi-dose, double-blind, placebo-controlled study performed in 16  healthy volunteers  were presented at the 52nd ICAAC meeting in San Francisco, CA. Ceftolozane + tazobactam administration was safe and well tolerated [&lt;ulink linkID="1320002" linkType="Reference"&gt;1320002&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt; In January 2011, a phase I epithelial lining fluid study which would provide input for the design of registration trials in nosocomial pneumonia had been initiated [&lt;ulink linkID="1162543" linkType="Reference"&gt;1162543&lt;/ulink&gt;]; by June 2011, the trial had been completed [&lt;ulink linkID="1200650" linkType="Reference"&gt;1200650&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Complicated urinary tract infections&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In June 2016, post-hoc analysis data were presented from two large, multicenter, multinational, double-blind, randomized, non-inferiority, phase III programs (ASPECT-cIAI: NCT01445665, NCT01445678; ASPECT-cUTI: NCT01345929, NCT01345955) to evaluate ceftolozane + tazobactam were presented at the 2016 ASM Microbe Conference in Boston, MA. Cure rates were lower in patients with diabetes (n = 198) when compared with non-diabetic patients (n = 1408). Although, high levels of complications in patients with diabetes, including cardiac and renal disorders and additional ongoing infections, might have affected treatment outcomes, cure rates were comparable between treatment groups among patients with or without diabetes. The proportion of patients with clinical cure/composite cure rates among diabetic and non-diabetic patients was 75.4 and 86.1% in the cIAI microbiological intent-to-treat (MITT) population and cUTI modified MITT population, respectively. In diabetic patients, higher rates of TEAEs were likely due to comorbidities and higher incidences of infections and vascular disorders were observed.  No treatment-related TEAEs resulting in death was reported [&lt;ulink linkID="1770726" linkType="Reference"&gt;1770726&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2016, a single-group assignment, open-label, non-comparative phase III trial (&lt;ulink linkID="257725" linkType="Protocol"&gt;NCT02728089&lt;/ulink&gt;; 7625A-014; MK-7625A-014; 163276) was initiated in patients (n = 115) with uncomplicated phylonephritis and complicated UTI in Japan. The primary endpoint was percentage of participants with microbiological response of eradication at test of cure. The study was completed in September 2017 [&lt;ulink linkID="2110151" linkType="Reference"&gt;2110151&lt;/ulink&gt;]. In January 2019, results were reported showing 75.5% of bacterial efficacy to  UTI and 87.0% of clinical efficacy for intraabdominal infection [&lt;ulink linkID="2109713" linkType="Reference"&gt;2109713&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In October 2015, clinical data from the pooled phase III ASPECT-cUTI studies (NCT01345929, NCT01345955) which assessed the efficacy and in vitro activity of ceftolozane + tazobactam against piperacillin + tazobactam or ceftazidime non-susceptible Enterobacteriaceae pathogens and also isolates collected from surveillance centers in Europe, North America and Australia from 2011 to 2013 were presented at the 2015 IDWeek in San Diego, CA. Clinical cure rates were high in ceftolozane + tazobactam-treated patients with cUTI caused by piperacillin + tazobactam or ceftazidime non-susceptible Enterobacteriaceae pathogens (Enterobacter spp., E coli, K pneumoniae) with no in vitro activity (46 to 68%) correlation; and exhibited greater in vitro activity against 40 to 50% surveillance Enterobacteriaceae pathogens [&lt;ulink linkID="1704323" linkType="Reference"&gt;1704323&lt;/ulink&gt;]. In October 2015, further clinical data were presented at the 2015 IDWeek in San Diego, CA. Against Enterobacteriaceae and E coli, ceftolozane/tazobactam had MIC50 value of 0.5 and 0.5, respectively when compared with levofloxacin (&amp;gt; 4 and &amp;gt; 4, respectively) and MIC90 value of &amp;gt; 64 and 1, respectively when compared with levofloxacin (&amp;gt; 4 and &amp;gt; 4, respectively) in patients with complicated pyelonephritis and MIC50 value of 0.5 and 0.5, respectively when compared with levofloxacin (&amp;gt; 4 and &amp;gt; 4, respectively) and MIC90 value of 8 and 1, respectively when compared with levofloxacin (&amp;gt; 4 and &amp;gt; 4, respectively) in patients with uncomplicated pyelonephritis [&lt;ulink linkID="1704327" linkType="Reference"&gt;1704327&lt;/ulink&gt;]. Further clinical data were also presented at the same conference. Cure was observed in 93 and 81% of patients in ceftolozane/tazobactam + metronidazole group and in 81 and 78% of patients in meropenem group in patients with CrCL &amp;gt; 50 and 30 to 50 ml/min, respectively and response rates by renal function status was 97 and 87% in ceftolozane + tazobactam group and 94 and 80% meropenem group in patients with CrCL &amp;gt; 50 and 30 to 50 ml/min, respectively [&lt;ulink linkID="1703843" linkType="Reference"&gt;1703843&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2011, randomized, double-blind, active-controlled, phase III studies (&lt;ulink linkID="198127" linkType="Protocol"&gt;NCT01345929&lt;/ulink&gt; and &lt;ulink linkID="198127" linkType="Protocol"&gt;NCT01345955&lt;/ulink&gt;; CXA-cUTI-10-05 and CXA-cUTI-10-04) were initiated in patients in the US with cUTI, including pyelonephritis (expected n = 776), to assess the safety and efficacy of CXA-201 compared to &lt;ulink linkID="3492" linkType="Drug"&gt;levofloxacin&lt;/ulink&gt; [&lt;ulink linkID="1204826" linkType="Reference"&gt;1204826&lt;/ulink&gt;], [&lt;ulink linkID="1231928" linkType="Reference"&gt;1231928&lt;/ulink&gt;]. The study was  completed in mid-2013 [&lt;ulink linkID="1204826" linkType="Reference"&gt;1204826&lt;/ulink&gt;]. In November 2013, topline data showed that CXA-201 met its FDA-defined primary endpoint of non-inferiority to levofloxacin in composite of microbiological eradication and clinical cure rate at 5 to 9 days after the end of treatment; the 95% confidence interval around the treatment difference had lower and upper bounds of 2.3% and 14.6%, respectively, favoring ceftolozane/tazobactam and indicating superiority over levofloxacin. The spectrum of gram-negative pathogens seen in the trial was comparable with other clinical trials in patients with cUTI. Additionally the primary endpoint in the EU of non-inferiority based on microbiological eradication was also met [&lt;ulink linkID="1502573" linkType="Reference"&gt;1502573&lt;/ulink&gt;]. In May 2014, similar data were presented at the 24th ECCMID Annual Meeting in Barcelona, Spain [&lt;ulink linkID="1553673" linkType="Reference"&gt;1553673&lt;/ulink&gt;]. In September 2014, similar data from the ASPECT-cUTI trial were presented at the 54th ICAAC Meeting in Washington, DC [&lt;ulink linkID="1589241" linkType="Reference"&gt;1589241&lt;/ulink&gt;]. In October 2014, further data were presented at the 2014 IDWeek in Philadelphia, PA.											Clinical cure rate with ceftolozane/tazobactum was higher (97.1%) compared with 84.7% in all patients with extended spectrum beta-lactamases and 98.1% compared with 82.6% in cUTI patients with ESBLs [&lt;ulink linkID="1599610" linkType="Reference"&gt;1599610&lt;/ulink&gt;]. From the same conference data were presented.  In a subset of patients with levofloxacin-resistant E coli and K pneumonia, ceftolozane/tazobactam showed superior microbiological eradication rates compared with levofloxacin and in patients with levofloxacin-resistant P aeruginosa, 100% microbiological eradication rate was reported [&lt;ulink linkID="1599528" linkType="Reference"&gt;1599528&lt;/ulink&gt;]. 	In April 2015, further clinical data were presented from 812 patients at the 25th ECCMID in Copenhagen, Denmark.																		 In  microbiologically evaluable patients, clinical cure rates for ceftolozane + tazobactam were 95.2% compared to 92.4% with levofloxacin.  In addition, ceftolozane + tazobactam showed high microbiological eradication for uropathogens Escherichia coli, K pneumoniae and P aeruginosa. In general, ceftolozane + tazobactam combination was safe and well-tolerated [&lt;ulink linkID="1653614" linkType="Reference"&gt;1653614&lt;/ulink&gt;]. In September 2015, further data were presented at the 2015 ICAAC/ICC Meeting in San Diego, CA. Clinical cure and eradication rates for ceftolozane/tazobactam were higher for Enterobacteriaceae (97.4%) and P aeruginosa  (88.9%) from cUTI patients [&lt;ulink linkID="1694056" linkType="Reference"&gt;1694056&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;By January 2011, phase II studies had been initiated [&lt;ulink linkID="1180505" linkType="Reference"&gt;1180505&lt;/ulink&gt;]. In March 2011, it was reported at the 13th SMi Superbugs &amp;amp; Superdrugs Conference that phase II studies were ongoing in cUTI patients [&lt;ulink linkID="1180470" linkType="Reference"&gt;1180470&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2009, a program for cUTI was to be advanced in 1H10 [&lt;ulink linkID="1063881" linkType="Reference"&gt;1063881&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Complicated intra-abdominal  infections&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In June 2016, post-hoc analysis data were presented from two large, multicenter, multinational, double-blind, randomized, non-inferiority, phase III programs (ASPECT-cIAI: NCT01445665, NCT01445678; ASPECT-cUTI: NCT01345929, NCT01345955) to evaluate ceftolozane + tazobactam were presented at the 2016 ASM Microbe Conference in Boston, MA. Cure rates were lower in patients with diabetes (n = 198) when compared with non-diabetic patients (n = 1408). Although, high levels of complications in patients with diabetes, including cardiac and renal disorders and additional ongoing infections, might have affected treatment outcomes, cure rates were comparable between treatment groups among patients with or without diabetes. The proportion of patients with clinical cure/composite cure rates among diabetic and non-diabetic patients was 75.4 and 86.1% in the cIAI microbiological intent-to-treat (MITT) population and cUTI modified MITT population, respectively. In diabetic patients, higher rates of TEAEs were likely due to comorbidities and higher incidences of infections and vascular disorders were observed.  No treatment-related TEAEs resulting in death was reported [&lt;ulink linkID="1770726" linkType="Reference"&gt;1770726&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2016, a multicenter, open-label, noncomparative,  phase III study (&lt;ulink linkID="258373" linkType="Protocol"&gt;NCT02739997&lt;/ulink&gt;; 7625A-013  MK-7625A-013) to evaluate the efficacy and safety of ceftolozane and tazobactam used in combination with metronidazole in Japanese patients with complicated intra-abdominal infection, was initiated. The trial was to complete in August 2017 [&lt;ulink linkID="1755020" linkType="Reference"&gt;1755020&lt;/ulink&gt;]. In January 2019, results were reported showing 87.0% clinical efficacy for intra-abdominal infection [&lt;ulink linkID="2109713" linkType="Reference"&gt;2109713&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In October 2015, clinical data from the pooled phase III ASPECT-cIAI studies ( NCT01445665, NCT01445678) which assessed the efficacy and in vitro activity of ceftolozane + tazobactam against piperacillin + tazobactam or ceftazidime non-susceptible Enterobacteriaceae pathogens and also isolates collected from surveillance centers in Europe, North America and Australia from 2011 to 2013 were presented at the 2015 IDWeek in San Diego, CA. Clinical cure rates were high in ceftolozane + tazobactam-treated patients with cIAI caused by piperacillin + tazobactam or ceftazidime non-susceptible Enterobacteriaceae pathogens (Enterobacter spp., E coli, K pneumoniae) with no in vitro activity (46 to 68%) correlation; and exhibited greater in vitro activity against 40 to 50% surveillance Enterobacteriaceae pathogens [&lt;ulink linkID="1704323" linkType="Reference"&gt;1704323&lt;/ulink&gt;]. Further clinical data were also presented at the same conference. Cure was observed in 85 and 48% of patients in ceftolozane/tazobactam + metronidazole group and in 88 and 69% of patients in meropenem group in patients with CrCL &amp;gt; 50 and 30 to 50 ml/min, respectively and response rates by renal function status was 95 and 73% in ceftolozane + tazobactam group and 95 and 71% in meropenem group in patients with CrCL &amp;gt; 50 and 30 to 50 ml/min, respectively [&lt;ulink linkID="1703843" linkType="Reference"&gt;1703843&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By October 2011, enrollment had begun in one of two pivotal global phase III trials  [&lt;ulink linkID="1231928" linkType="Reference"&gt;1231928&lt;/ulink&gt;]; the multicenter, double-blind, randomized, phase III trial (&lt;ulink linkID="81283" linkType="Protocol"&gt;NCT01445665&lt;/ulink&gt;; CXA-cIAI-10-08) began in the US, Australia, Europe, South America, Mexico and South Africa, and was to compare CXA-201 plus metronidazole with &lt;ulink linkID="3616" linkType="Drug"&gt;meropenem&lt;/ulink&gt; to assess the safety/efficacy in patients (expected n = 500) with cIAI. The primary endpoint was the proportion of subjects with clinical outcome of cure. At that time, the trial was expected to complete in March 2013  [&lt;ulink linkID="1248352" linkType="Reference"&gt;1248352&lt;/ulink&gt;]. In December 2011, the first patient was dosed in the 780-patient  trial   [&lt;ulink linkID="1248173" linkType="Reference"&gt;1248173&lt;/ulink&gt;]. Also in December 2011, a second multicenter, double-blind, randomized, phase III trial (&lt;ulink linkID="81283" linkType="Protocol"&gt;NCT01445678&lt;/ulink&gt;; CXA-cIAI-10-09) began in the US, South America, Europe, Israel and Korea in patients (expected n = 494) with cIAI, and was to compare CXA-201 plus metronidazole with meropenem.  The primary endpoint was the proportion of subjects with clinical outcome of cure. At that time, the trial was expected to complete in  April 2013 [&lt;ulink linkID="1509620" linkType="Reference"&gt;1509620&lt;/ulink&gt;]. In December 2013, topline data from both studies in 993 patients were reported, showing that the primary endpoints of a clinical cure rate 26 to 30 days after therapy initiation were met and CXA-201 plus metronidazole  was statistically non-inferior to meropenem; for the FDA-defined primary endpoint in the microbiological intent-to-treat population, the non-inferiority margin was 10%, and for the EMA-defined primary endpoint in clinically evaluable patients, the non-inferiority margin was 12.5%. At that time, full results were expected in the future [&lt;ulink linkID="1509279" linkType="Reference"&gt;1509279&lt;/ulink&gt;]. 	In May 2014, pooled clinical data from two phase III studies (NCT01445665 and NCT01445678; the ASPECT-cIAI phase III program) were presented at the 24th ECCMID Annual Meeting in Barcelona, Spain. Hospitalized patients (n = 993) with complicated intra-abdominal infections  requiring surgical intervention were randomized to receive CXA-201 (ceftolozane/tazobactam 1000/500 mg q8h) plus &lt;ulink linkID="55388" linkType="Drug"&gt;metronidazole&lt;/ulink&gt; (500 mg q8h) or meropenem (1 g q8h) and placebo. The clinical cure rates at the test-of-cure visit with CXA-201 in combination with metronidazole were non-inferior to those observed for meropenem in the clinically evaluable, intent-to-treat, microbiological intent-to-treat and microbiologically evaluable populations. Clinical cure for ESBL-producing Enterobacteriaceae was achieved in 100 and 88.5% of patients receiving CXA-201/metronidazole and meropenem, respectively [&lt;ulink linkID="1555644" linkType="Reference"&gt;1555644&lt;/ulink&gt;], [&lt;ulink linkID="1555599" linkType="Reference"&gt;1555599&lt;/ulink&gt;]. In October 2014, further data were presented at the 2014 IDWeek in Philadelphia, PA.											In patients who had P aeruginosa at baseline, showed clinical cure of 100 and 96.4%, who do not have P aeruginosa at baseline, showed clinical cure of 93.6 and 94.5%, with ceftolozane/tazobactum + metronidazole and meropenam, respectively [&lt;ulink linkID="1599609" linkType="Reference"&gt;1599609&lt;/ulink&gt;].  From the same conference data were presented. Clinical cure rates with ceftolozane/tazobactum was higher (97.1%) compared with extended spectrum beta-lactamases (84.7%) in all patients [&lt;ulink linkID="1599610" linkType="Reference"&gt;1599610&lt;/ulink&gt;]. In February 2015, similar data were published; the overall clinical cure rate was 83.0% for CXA-201+metronidazole versus 87.3% for meropenem in the microbiological intent-to-treat population, and 94.1 versus 94.0% in the microbiologically evaluable population [&lt;ulink linkID="1659226" linkType="Reference"&gt;1659226&lt;/ulink&gt;]. In April 2015, further clinical data were presented at the 25th ECCMID in Copenhagen, Denmark. At the test-of-cure visit, clinical cure rates were similar between obese (84.3%) and non-obese (83.8%) patients in ceftolozane/tazobactam + metronidazole group, while these were 82.3 and 87.5%, respectively, in meropenem group [&lt;ulink linkID="1653480" linkType="Reference"&gt;1653480&lt;/ulink&gt;]. In September 2015, similar data were presented at the 2015 ICAAC/ICC Meeting in San Diego, CA [&lt;ulink linkID="1694056" linkType="Reference"&gt;1694056&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In April 2018, a randomized, active comparator-controlled, multicenter, double-blind, phase II trial (&lt;ulink linkID="304761" linkType="Protocol"&gt;NCT03217136&lt;/ulink&gt;; 7625A-035; EudraCT: 2016-004820-41; MK-7625A-035) was initiated in the US, Russia, South Africa, Turkey, Europe, Mexico and Malaysia to assess the safety and efficacy of ceftolozane/tazobactam (MK-7625A) plus metronidazole versus meropenem in pediatric patients (expected n = 120) with cIAI. The primary endpoints were adverse events up to day 42 and study discontinuations due to adverse events up to day 14. The trial was expected to complete in September 2020 [&lt;ulink linkID="2077729" linkType="Reference"&gt;2077729&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2010, a multicenter, double-blind, randomized, phase II trial (&lt;ulink linkID="67596" linkType="Protocol"&gt;NCT01147640&lt;/ulink&gt;; CXA-IAI-10-01) was initiated for cIAI. A total of 120 patients would be treated with an iv infusion of CXA-201 (1000/500 mg q8h) plus metronidazole (1000 mg q8h) in arm1, meropenem (1000 mg q8h) or placebo in arm2 [&lt;ulink linkID="1112033" linkType="Reference"&gt;1112033&lt;/ulink&gt;], [&lt;ulink linkID="1111961" linkType="Reference"&gt;1111961&lt;/ulink&gt;]. In June 2011, top-line data from the 122-patient trial were reported. CXA-201 was safe, efficacious, well tolerated and met its primary objective of clinical response and secondary objective of microbiological response. Clinical cure rates were 91 and 94% for CXA-201 and meropenem, respectively. Clinical cure rates across the identified baseline pathogens including E coli, K pneumonia and P aeruginosa were 89 and 96% for CXA-201 and meropenem, respectively [&lt;ulink linkID="1200650" linkType="Reference"&gt;1200650&lt;/ulink&gt;]. In September 2013, data were presented at the 53rd ICAAC Meeting in Denver, CO. The clinical cure rates at test of cure (TOC) in microbiologically evaluable (ME) patients were 88.7 and 95.8% in arm1 and arm2, respectively. In ME patients, microbiological success rates at TOC were found to be 90.6 and 95.8% in arm1 and arm2, respectively [&lt;ulink linkID="1472982" linkType="Reference"&gt;1472982&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In February 2015, a prospective, multicenter, open-label, non-randomized, phase I study (&lt;ulink linkID="224346" linkType="Protocol"&gt;NCT02387372&lt;/ulink&gt;;  7625A-007;  CXA-ICU-14-01)  began to evaluate pharmacokinetics and lung penetration in critically ill patients (expected n = 35) with pneumonia in the US and Europe. In March 2017, the study was to complete in June 2017 [&lt;ulink linkID="1911901" linkType="Reference"&gt;1911901&lt;/ulink&gt;]. In April 2017, further data were presented at the 27th ECCMID in Vienna, Austria. In Patients treated with first and last doses of ceftolozane, AUC 0 to 8 observed was 216 and 318 microg.h/ml, respectively; Cmax observed was 66.2 and 82.3 microg/ml, respectively. No study discontinuation due to AEs was observed [&lt;ulink linkID="1920452" linkType="Reference"&gt;1920452&lt;/ulink&gt;]. In October 2017, further data were presented at the 2017 IDWeek in San Diego, CA. Ceftolozance AUC demonstrated a plasma accumulation of approximately 1.5-fold following multiple-dose administration. Tazobactam AUC exhibited a minimal plasma accumulation of approximately 1.1-fold after multiple-dose administration. A total of 36 adverse events (AEs) were reported by 13 patients, of which none were deemed as serious according to investigators [&lt;ulink linkID="1968097" linkType="Reference"&gt;1968097&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By January 2011, enrollment had begun in a phase I epithelial lining fluid (ELF) study which would provide input for the design of planned registration trials in nosocomial pneumonia [&lt;ulink linkID="1162543" linkType="Reference"&gt;1162543&lt;/ulink&gt;]; by June 2011, the trial had been completed. Data demonstrated good lung penetration of CXA-101. ELF concentrations of CXA-101 exceeded 8 microg/ml [&lt;ulink linkID="1200650" linkType="Reference"&gt;1200650&lt;/ulink&gt;]. In April 2012, similar data were presented at the 22nd ECCMID in London, UK [&lt;ulink linkID="1274768" linkType="Reference"&gt;1274768&lt;/ulink&gt;], [&lt;ulink linkID="1276716" linkType="Reference"&gt;1276716&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In September 2010, date from a phase I, randomized, double-blind, crossover-assignment, dose-escalation, pharmacokinetics study were presented at the 50th ICAAC meeting in Boston, MA. Following iv infusion in healthy subjects (n = 18), the drug was found to be extensively distributed in body fluids and  primarily excreted by the kidneys. Administration of CXA-201 did not result in an altered pharmacokinetic profile compared to those of &lt;ulink linkID="21303" linkType="Drug"&gt;CXA-101&lt;/ulink&gt; and tazobactam alone, and the metabolism and urinary excretion of the drug were also unaffected [&lt;ulink linkID="1126316" linkType="Reference"&gt;1126316&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;By September 2009, a phase I trial was underway [&lt;ulink linkID="1069268" linkType="Reference"&gt;1069268&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2016, a clinical trial application was filed in China, presumably for cIAI [&lt;ulink linkID="1739793" linkType="Reference"&gt;1739793&lt;/ulink&gt;]. In March 2017, review of the application was concluded though the outcome was not published yet [&lt;ulink linkID="1910079" linkType="Reference"&gt;1910079&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Miscellaneous&lt;/subtitle&gt;In January 2019, pooled safety data were reported from  two phase III trials (NCT02739997 and NCT02728089) conducted in Japan. The major adverse events reported were  increased ALT (GPT) (7.0%), increased AST (GOT) (7.0%), diarrhea (4.2%), nausea (1.4%) and increased gamma-GTP (1.4%) [&lt;ulink linkID="2109713" linkType="Reference"&gt;2109713&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In October 2018, data from a retrospective cohort analysis of a multicenter, comparative effectiveness study which compared the efficacy of ceftolozane + tazobactam versus polymyxin or aminoglycoside-based regimens for the potential treatment of serious infections due to multidrug resistance/extensively drug resistant Pseudomonas aeruginosa were presented at the 2018 IDWeek in San Francisco, CA. In ceftolozane/tazobactum versus polymyxin/aminoglycoside groups, combination therapy was susceptible in 100 versus 33% of patients, respectively; clinical cure (resolution of the signs and symptoms of infection without needing to modify therapy based on failure or toxicity) was obwerved in 81 versus 61% of patients, respectively (p = 0.006); in hospital mortality was reported in 21 versus 26% of patients, respectively (p = 0.46); and acute kidney injury was reported in 6 versus 34% of patients, respectively (p = &amp;lt; 0.001)  [&lt;ulink linkID="2078059" linkType="Reference"&gt;2078059&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2017, preclinical data from an in vitro study of ceftolozane/tazobactam performed as part of the Program to Assess Ceftolozane-Tazobactam Susceptibility (PACTS) were presented at the 27th ECCMID in Vienna, Austria. Overall, 18,285 Gram-negative bacilli including 13,289 Enterobacteriaceae and 3284 P aeruginosa were collected from 42 European hospitals from 2014 to 2016. At the susceptibility breakpoint of &amp;lt;/= 1 mg/l, ceftolozane/tazobactam inhibited 88.4% of Enterobacteriaceae. Overall, 90.1% of P aeruginosa isolates were inhibited by ceftolozane/tazobactam at the susceptibility breakpoint of &amp;lt;/= 4 mg/l. Out of 1040 MDR P aeruginosa isolates, colistin and ceftolozane/tazobactam appeared to be the most active drugs (percentage susceptibility = 98.8 and 69.6%, respectively), whereas 51.3 and &amp;lt;/= 40% of isolates being susceptible to amikacin and the remaining drugs, respectively [&lt;ulink linkID="1920334" linkType="Reference"&gt;1920334&lt;/ulink&gt;]. Further results from an analysis of 1821 Enterobacteriaceae and 484 P aeruginosa isolates collected from 13 Latin American hospitals between 2014 and 2016 were presented at the same conference. At the susceptibility breakpoint of &amp;lt;/= 1 mg/l, ceftolozane/tazobactam inhibited 86.2% of Enterobacteriaceae (MIC50/90 = 0.25/4 mg/l). Only slight variations were observed in the susceptibility to ceftolozane/tazobactam, with lowest in Brazil and Chile and highest in Guatemala (81.2 and 97.5%, respectively). For P aeruginosa, 92.6% of isolates were inhibited by ceftolozane/tazobactam at &amp;lt;/= 4 mg/l (MIC50/90 = 0.5/4 mg/l) [&lt;ulink linkID="1920507" linkType="Reference"&gt;1920507&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2016, clinical data from a non-comparative, interventional, multicenter, phase I study (&lt;ulink linkID="213773" linkType="Protocol"&gt;NCT02266706&lt;/ulink&gt;) were presented at the 2016 IDWeek in New Orleans, LA. Patients with 12 to 18 years of age (group 1; n= 6) received single iv infusion of 1.5 g ceftolozane/tazobactam dose (1000 mg ceftolozane/500 mg tazobactam); with 7 to &amp;lt; 12 years of age (group 2; n = 6) received 18 mg/kg of ceftolozane and 9 mg/kg of tazobactam; with 2 to &amp;lt; 7 (group 3; n = 6) and 3 months of &amp;lt; 2 years of age (group 4; n = 6) received 30 mg/kg of ceftolozane and 15 mg/kg of tazobactam. For group-3 and 4, initial dose of ceftolozane was 18 mg/kg and of tazobactam was 9 mg/kg; this was increased following an interim analysis for group 3. The exposures of ceftolozane/tazobactam at fixed dose of 1.5g and 30/15 mg/kg were similar to those in adults. In group-2 patients, lower exposures were observed. None of the patient discontinued prematurely from the study drug or the study because of adverse events. At that time, enrollment was ongoing for groups 5 (from birth [&amp;gt; 32 week gestation and 7 day post natal] to &amp;lt; 3 months) and 6 (from birth [&amp;lt;/= 32 week gestation and 7 day post natal] to &amp;lt; 3 months) [&lt;ulink linkID="1866282" linkType="Reference"&gt;1866282&lt;/ulink&gt;]. In October 2017, further subgroup exploratory analysis data were presented at 2017 IDWeek in San Diego, CA. Between patients with and without CF, significant difference in ceftolozane weight-normalized pharmacokinetic parameters was not achieved. Compared to patients without CF, patients with CF achieved higher tazobactam weight-normalized clearance. However, similar t1/2 was achieved in both patients with and without CF, which suggested that differences in clearances were unlikely to be clinically meaningful [&lt;ulink linkID="1968067" linkType="Reference"&gt;1968067&lt;/ulink&gt;].  Further data were presented at the same conference. Ceftolozane/tazobactam showed AUC (0 to infinity) of 171 and 22.5 microg h/ml, respectively; Cmax of 45.5 and 11.9 microg/ml, respectively; Tmax of 1.0 and 1.0 h, respectively; t/12 of 2.39 and 1.13 h, respectively; clearance was 0.13 and 0.42 l/kg/l, respectively; Vss was 0.41 and 0.71 l/kg, respectively. Hypokalemia, constipation, periorbital edema, anemia, and failed extubation were the adverse events reported, which were all moderate in severity, not drug related, and resolved/recovered [&lt;ulink linkID="1968141" linkType="Reference"&gt;1968141&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;In October 2013,  data from an open-label, phase I study  were presented at IDWeek 2013 in San Francisco, CA. Healthy subjects with severe renal impairment (SRI; n = 6) received ceftolozane + tazobactam as 1 h intravenous infusion and end-stage renal disease (ESRD) subjects received two doses of ceftolozane + tazobactam (500 mg/250 mg). Plasma exposure to ceftolozane + tazobactam was increased by SRI leading to dose reduction. In ESRD patients, hemodialysis removed ceftolozane + tazobactam from the plasma. Ceftolozane + tazobactam was well tolerated [&lt;ulink linkID="1481954" linkType="Reference"&gt;1481954&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In September 2011, pooled data on renally impaired patients from phase I and II studies were presented at the 51st ICAAC meeting in Chicago, IL. A 1-h infusion of CXA-201 1000/500 mg q8h was appropriate in patients with mild renal impairment. A 50% dose reduction (500/250 mg q8h) in patients with moderate renal impairment achieved 100% probability of target attainment and similar exposures. Less frequent dosing in patients with severe renal impairment would  limit exposure without compromising probability of target attainment [&lt;ulink linkID="1219995" linkType="Reference"&gt;1219995&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2011, clinical data were presented from a study in mild or moderate renal impairment  patients (n = 24) for the treatment of serious infections due to drug-resistant P aeruginosa     at the 21st ECCMID/27th ICC in Milan, Italy.  Optimal target attainment rates were achieved in subjects with normal renal function (NRF) or mild or moderate renal function while maintaining similar exposure. A 50% reduction in those with moderate renal function provided plasma concentrations of CXA-101 (iv infusion), tazobactam and metabolite M-1 similar to those with NRF with excellent target attainment [&lt;ulink linkID="1217511" linkType="Reference"&gt;1217511&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In April 2019, in vitro data were presented at the 29th  ECCMID in Amsterdam, the Netherlands. Against 20 well-characterized extensively drug-resistant P aeruginosa clinical isolates selected from a prospective COLIMERO study, ceftolozane/tazobactam exhibited MICs ranging from 1/4 to &amp;gt; 64/4 microg/ml and colistin exhibited MIC ranging from 0.5 to 4 microg/ml.  In time-kill studies using 1.0 x 10(7) CFU/ml starting inoculums, ceftolozane/tazobactam in combination with colistin was synergistic and additive in 55 and 90% of the isolates, respectively [&lt;ulink linkID="2140370" linkType="Reference"&gt;2140370&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In April 2019, in vitro data were presented at the 29th ECCMID in Amsterdam, the Netherlands. Ceftolozane/tazobactam inhibited 66.2% of the MDR P aeruginosa strains &amp;lt;/= 4 mg/l (MIC50/90: 2/32 mg/l). Ceftolozane/tazobactam showed synergistic activity with amikacin for all isolates with MIC of &amp;lt;/= 8 mg/l. A total of 83% isolates and 1 isolate showed synergistic activity with MICs of &amp;lt;/= 16 and 32 mg/l, respectively [&lt;ulink linkID="2150344" linkType="Reference"&gt;2150344&lt;/ulink&gt;]. At the same conference, additional preclinical data were presented. For Pseudomonas aeruginosa, ceftolozane/tazobactam displayed an overall susceptibility rate of 85 to 95% based on the geographic location, for Enterobacteriaceae isolates, the overall susceptibility rate was 79 to 92%. Ceftolozane/tazobactam maintained activity against 83% of ESBL + E coli and against 54 to 63% of global P aeruginosa isolates non-susceptible to other beta-lactams. Substantially higher susceptibility was seen in isolates collected from the US and Canada [&lt;ulink linkID="2150316" linkType="Reference"&gt;2150316&lt;/ulink&gt;]. Further in vitro data were presented at the same conference.  Ceftolozane/tazobactam  was found to be most active against P aeruginosa, with &amp;gt;/= 90% susceptibility for immunocompromized and patients aged &amp;gt; 65 years and &amp;gt; 80% susceptibility for ICU patients. Ceftolozane/tazobactam  susceptibility was &amp;gt; 95% for Escherichia coli, whereas meropenem showed &amp;gt; 98% susceptibility. Against Klebsiella pneumoniae, ceftolozane/tazobactam  and meropenem had &amp;lt; 75 and 78.9 to 85.8% susceptibility, respectively, while other antimicrobials tested showed lower percentage susceptibility [&lt;ulink linkID="2150338" linkType="Reference"&gt;2150338&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In October 2018, in vivo studies were presented at 2018 IDWeek in San Francisco, CA. In persistently neutropenia rabbits with experimental P aeruginosa pneumonia, including infections casued by strains with the most resistant mechanisms, ceftozolane/tazobactam treatment was highly active [&lt;ulink linkID="2078247" linkType="Reference"&gt;2078247&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;      In June 2017, in vitro data were presented at the 2017 ASM Microbe Conference in New Orleans, LA. Of 454 P aeruginosa isolates, ceftolozane/tazobactam exhibited good activity against 81.5% was susceptible to ceftolozane/tazobactam, 7.7% was intermediate and 10.8% was resistant. Of 351 MDR P aeruginosa isolates, 80.1% were susceptible to ceftolozane/tazobactam, 9.3% was intermediate and 11.7% was resistant [&lt;ulink linkID="1934270" linkType="Reference"&gt;1934270&lt;/ulink&gt;], [&lt;ulink linkID="1932804" linkType="Reference"&gt;1932804&lt;/ulink&gt;]. Further in vitro data were presented at the same conference. In E coli expressing PDC-3 beta-lactamase with specific amino acid substitutions within the omega-loop, elevated MIC values was observed for cephalosporins and monobactam beta-lactams including ceftolozane/tazobactam [&lt;ulink linkID="1934150" linkType="Reference"&gt;1934150&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In April 2017, preclinical data were presented at the 27th ECCMID in Vienna, Austria. Of 144 tested P aeruginosa isolates that were nonsusceptible or resistant to either ceftazidime and meropenem, ceftolozane-tazobactam at 4 mg/l was active against 84.7% isolates, while piperacillin-tazobactam showed activity against 50.7% isolates [&lt;ulink linkID="1920418" linkType="Reference"&gt;1920418&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2016, preclinical data were presented at the 26th ECCMID in Amsterdam, the Netherlands.  Ceftolozane/tazobactam was active against E coli, K pneumoniae and P aeruginosa isolated pathogens with MIC50/90 values of 0.25/0.5, 0.5/&amp;gt;32 and 0.5/4 mg/l, respectively [&lt;ulink linkID="1750205" linkType="Reference"&gt;1750205&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2015, preclinical data were presented at the 2015 ICAAC/ICC Meeting in San Diego, CA.  The MIC50/90 values of ceftolozane/tazobactam against various Gram-negative and –positive isolates were in the range of &amp;lt;/= 0.12/1 to 32/&amp;gt; 64 microg/ml when compared with other antibacterial drugs [&lt;ulink linkID="1693326" linkType="Reference"&gt;1693326&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt; In September 2015, preclinical data were presented at the 2015 ICAAC/ICC Meeting in San Diego, CA. Ceftolozane/tazobactam showed activity (MIC50/90, USA 0.25/1, EU 0.25/2 microg/ml) against  Enterobacteriaceae  with susceptibility rates of 94.6 (USA) and 91.4% (EU) [&lt;ulink linkID="1692693" linkType="Reference"&gt;1692693&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2015, preclinical data were presented at the 25th ECCMID in Copenhagen, Denmark. At &amp;lt; 2 and &amp;lt; 4 mg/l of ceftolozane + tazobactam inhibited 91.7 and 93.4% of Enterobacteriaceae, respectively. Against multidrug-resistant (MDR) strains of ceftolozane + tazobactam was up to 32-fold more potent compared with other agents [&lt;ulink linkID="1654666" linkType="Reference"&gt;1654666&lt;/ulink&gt;]. Further preclinical data were presented at the same conference. P aeruginosa strains were inhibited (91.5 and 93.4%) by ceftolozane + tazobactam at &amp;lt; 4 + 4 and &amp;lt; 8 + 4 mg/l, respectively and ceftolozane + tazobactam was the most potent agent next to colistin. Ceftolozane + tazobactam retained  activity against many multidrug-resistant and extensively drug-resistant strains [&lt;ulink linkID="1654664" linkType="Reference"&gt;1654664&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2014, preclinical data were presented at the 2014 IDWeek in Philadelphia, PA.											Ceftolozane/tazobactum was very active against aerobic gram-negative bacteria including Enterobacteriaceae, E coli, Klebsiella spp., Citrobacter spp., P mirabilis, Serratia marcescens  and P aeruginosa with MIC50/90 values in the range of 0.25 to 4/0.5 to &amp;gt; 64 microg/ml, respectively [&lt;ulink linkID="1599535" linkType="Reference"&gt;1599535&lt;/ulink&gt;]. From the same conference data were presented. Ceftolozane/tazobactum inhibited 86.2% of multidrug-resistant and 77.1% of extensively drug-resistant  P aeruginosa isolates at MICs of &amp;lt;/= 8 microg/ml [&lt;ulink linkID="1598858" linkType="Reference"&gt;1598858&lt;/ulink&gt;]. From the same conference data were presented. Ceftolozane/tazobactam had MIC90 value of 32 mg/l and susceptible value of 86% against MDR P aeruginosa [&lt;ulink linkID="1599585" linkType="Reference"&gt;1599585&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2014, preclinical data were presented at the 54th ICAAC Meeting in Washington, DC. Against various Enterobacteriaceae and Pseudomonas aeroginase strains, ceftolozane/tazobactum showed susceptibility values of 90 and 94%, respectively. Against non-susceptible piperacillin/tazobactum population, ceftolozane/tazobactum demonstrated high potency as greater than 70% of these pathogens had MIC values &amp;lt;= 2 mg/l [&lt;ulink linkID="1589010" linkType="Reference"&gt;1589010&lt;/ulink&gt;]. Further data were presented at the same conference. The lowest dose of ceftolozane/tazobactum failed without amplifying drug resistance as it was not able to kill the total population, the intermediate dose failed as the drug-resistant bacteria subpopulations were amplified [&lt;ulink linkID="1589938" linkType="Reference"&gt;1589938&lt;/ulink&gt;]. Further data were presented at the same conference. Against 1081 Pseudomonas aeroginosa isolates tested, ceftolozane/tazobactum showed potent antibacterial activity (MIC50/90 = 0.5/2 microg/ml), inhibiting 98.2% of isolates at MIC value of &amp;lt;/= 8 microg/ml. Ceftolozane/tazobactum exhibited 4-fold higher activity than cefepime, 16-fold higher activity than pipercillin/tazobactum, while showed slightly more activity than meropenem and doripenem [&lt;ulink linkID="1589026" linkType="Reference"&gt;1589026&lt;/ulink&gt;]. Further data were presented at the same conference. Against 4051 Enterobacteriaceae isolates tested, ceftolozane/tazobactum inhibited 95.2 and 96.5% of strains at &amp;lt;/= 4 and &amp;lt;/= 8 microg/ml, respectively. Ceftolozane/tazobactum showed activity against multidrug-resistant and extensively drug-resistant [&lt;ulink linkID="1589052" linkType="Reference"&gt;1589052&lt;/ulink&gt;]. Further data were presented at the same conference. Against various bacterial isolates, ceftolozane/tazobactum showed potent activity with MIC values in the range of &amp;lt;/= 0.12 to &amp;gt; 64 microg/ml [&lt;ulink linkID="1589018" linkType="Reference"&gt;1589018&lt;/ulink&gt;]. Further data were presented at the same conference. Against isolates of Enterobacteriaceae, Pseudomonas aeroginosa and Streptococci species, ceftolozane/tazobactum exhibited potent bactericidal activity [&lt;ulink linkID="1589232" linkType="Reference"&gt;1589232&lt;/ulink&gt;]&lt;/para&gt;&lt;para&gt;In September 2013, preclinical data were presented at the 53rd ICAAC Meeting in Denver, CO. Against E coli-10909/NIHJ (fully susceptible), E. coli-44913 (ampicillin resistant), P aeruginosa-38475 (no ceftolozane resistance mechanisms) and E. coli-47204 (CTX-M producer) strains , ceftolozane + tazobactam demonstrated unchanged fT&amp;gt;MIC (duration that the unbound concentration of an antibiotic remains above the MIC as a percentage of the dosing interval) values for 24 h bacteriostatic and bacteriocidal effects, when compared with the ceftolozane alone [&lt;ulink linkID="1472911" linkType="Reference"&gt;1472911&lt;/ulink&gt;]. Further data were presented at the same conference. The post beta-lactamase inhibitor effects of ceftolozane/tazobactam against E coli clinical strains 136-4643A and 107-5846A were observed for 2.1 and 1.3 h, respectively [&lt;ulink linkID="1472912" linkType="Reference"&gt;1472912&lt;/ulink&gt;]. The highest doses of ceftolozane/tazobactam (750/375, 1000/500 and 1500/750 mg) successfully killed the total bacterial population and prevented the emergence of drug-resistant bacteria subpopulations [&lt;ulink linkID="1472914" linkType="Reference"&gt;1472914&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In September 2013, preclinical data were presented at the 53rd ICAAC Meeting in Denver, CO. The MIC values of ceftolozane + tazobactam were 0.5, 0.5, 2.0 and 4.0 mg/l against 4643A, 1801 A, 21711R and 13319R strains of E coli, respectively, and 1.0, 2.0 and 4.0 mg/l against 604C, 21904E and 4812E strains of K pneumoniae, respectively [&lt;ulink linkID="1472915" linkType="Reference"&gt;1472915&lt;/ulink&gt;]. Further data from studies in CTX-M producing E coli isolates were presented at the same conference. Ceftolozane in combination with 4 microg/ml of tazobactam showed 128-fold lower MIC value when compared with ceftolozane alone, and had MIC50 value of &amp;lt;/= 0.25 microg/ml and MIC90 value of 0.5 microg/ml against all CTX-M-type producing E coli isolates tested [&lt;ulink linkID="1472990" linkType="Reference"&gt;1472990&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In September 2013, preclinical data from studies in the neutropenic mouse thigh model of gram-negative bacterial infection were presented at the 53rd ICAAC Meeting in Denver, CO. Administration of tazobactam every 2 h was more efficacious than every 8 h and reduced tazobactam daily dose by a factor of 4.1 [&lt;ulink linkID="1472919" linkType="Reference"&gt;1472919&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2013, preclinical data were presented at the 53rd ICAAC Meeting in Denver, CO. Ceftolozane/tazobactam (&amp;gt;/= 8 microg/ml) inhibited 94.1% of P aeruginosa strain, when compared with &lt;ulink linkID="3616" linkType="Drug"&gt;meropenem&lt;/ulink&gt; (73.7%), &lt;ulink linkID="44317" linkType="Drug"&gt;ceftazidime&lt;/ulink&gt; (73.6%), &lt;ulink linkID="2736" linkType="Drug"&gt;cefepime&lt;/ulink&gt; (76.5%), &lt;ulink linkID="29446" linkType="Drug"&gt;piperacillin/tazobactam&lt;/ulink&gt; (69.5%), &lt;ulink linkID="3492" linkType="Drug"&gt;levofloxacin&lt;/ulink&gt; (69.9%) and gentamicin (80.7%) [&lt;ulink linkID="1473127" linkType="Reference"&gt;1473127&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In September 2013, preclinical data were presented at the 53rd ICAAC Meeting in Denver, CO. Ceftolozane/tazobactam showed potent activity against clinical isolates of Enterobacteriaceae, Haemophilus influenzae, Streptococcus pneumoniae and Acinetobacter baumannii when compared with piperacillin/tazobactam, ceftazidime, &lt;ulink linkID="44438" linkType="Drug"&gt;ciprofloxacin&lt;/ulink&gt; and &lt;ulink linkID="8642" linkType="Drug"&gt;tigecycline&lt;/ulink&gt; [&lt;ulink linkID="1472971" linkType="Reference"&gt;1472971&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2013, preclinical data were presented at the 23rd ECCMID  in Berlin, Germany. Against E coli producing low, moderate and high CTX-M-15 enzyme, the combination of ceftalozane/tazobactum (4 mg/l) showed potent activity with MIC value of 0.25 mg/l.   The %time &amp;gt; threshold was the pharmacodynamic-pharmacokinetic measure associated with efficacy. At 24 h, the reduction in 1- to 2-log(10) colony forming units  was increased with the increase in expression of beta-lactamase [&lt;ulink linkID="1407923" linkType="Reference"&gt;1407923&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2013, preclinical data were presented at the 23rd ECCMID  in Berlin, Germany. Ceftolozane/ tazobactum combination was 4-fold more active when compared with ceftazidime and was found to inhibit &amp;gt; 94% of P aeroginosa strains with MIC of &amp;lt;/= 8 mg/l in 8 European countries. At &amp;lt;/= 8 mg/l concentration, ceftolozane/ tazobactum inhibited 100% of strains in Ireland and 97.1% of strains in UK. In Poland, Russia and Ukraine, resistance to ceftolozane/ tazobactum was lower when compared with resistance to ceftazidime and meropenem [&lt;ulink linkID="1406518" linkType="Reference"&gt;1406518&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In  September 2012, preclinical data were presented at the 52nd ICAAC Meeting in San Francisco, CA. Against all strains of E coli tested, CXA-201 showed rapid bactericidal activity (99.9% kill). Against AmpC and CTXM15, concentration-dependent enhancement of ceftolozane was observed with increasing tazobactam concentrations, with more bactericidal activity apparent at 4 mg/l ceftolozane plus &amp;gt;/= 16 mg/l tazobactam [&lt;ulink linkID="1319130" linkType="Reference"&gt;1319130&lt;/ulink&gt;]. Further data presented at this conference demonstrated that against E coli, K pneumoniae, Enterobacter cloacae and Citrobacter freundii strains, ceftolozane alone had high MIC50 and 90 values (16 and &amp;gt;/= 64 mg/l, respectively). The 50/90th percentile concentration of tazobactam required to reduce the MIC of ceftolozane to 8 mg/l was 0.5/4 mg/l; against E coli, K pneumoniae and E cloacae, these values were 0.25/1, 0.5/8, and 0.5/4 mg/l, respectively. To reduce the MIC of ceftolozane to 1 mg/l against E coli, K pneumoniae and E cloacae, 1/4, 4/32 and, 8/&amp;gt;/= 32 mg/l of tazobactam were required [&lt;ulink linkID="1319126" linkType="Reference"&gt;1319126&lt;/ulink&gt;]. Additional data presented at this conference showed that ceftolozane/tazobactam was more potent than &lt;ulink linkID="44317" linkType="Drug"&gt;ceftazidime&lt;/ulink&gt;, cefepime and piperacillin/tazobactam against Pseudomonas and Enterobacteriaceae  strains obtained from USA hospitals  [&lt;ulink linkID="1319127" linkType="Reference"&gt;1319127&lt;/ulink&gt;]. Further data presented at this conference indicated that CXA-201 demonstrated potent in vitro activity against clinical isolates of Enterobacteriaceae, extended spectrum beta-lactamase  producing E coli and Haemophilus influenzae, Acinetobacter baumannii and P aeruginosa with MIC50/90 values of &amp;lt; 0.12/0.5, &amp;lt; 0.12/0.25, 0.5/2 and 0.5/1 microg/ml, respectively when compared with ceftazidime, ciprofloxacin, tigecycline and piperacillin-tazobactam. The combination also showed activity against K pneumoniae with MIC50/90 value of &amp;lt; 0.12/0.5 microg/ml [&lt;ulink linkID="1319128" linkType="Reference"&gt;1319128&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;In April 2012, preclinical data presented at the 22nd ECCMID in London, UK, showed the combination, from studies using broth microdilution against 3210 clinical strains isolated from European hospitals, to be overall 2- to 8-fold more active than ceftazidime, cefepime and piperacillin/tazobactam against P aeruginosa, including strains nonsusceptible to ceftazidime and meropenem. CXA-201 proved as potent as ceftazidime against extended-spectrum beta-lactamase-negative E coli and Klebsiella sp, but 16- to 32-fold more active against extended-spectrum beta-lactamase-producing strains. CXA-201 was also more active than ceftazidime against other gram-negative species. Additionally, compared with ceftolozane alone, ampicillin/sulbactam, piperacillin/tazobactam, imipenem, meropenem, moxifloxacin, tigecycline, clindamycin, metronidazole and linezolid, CXA-201 exhibited potent activity against all species of the Bacteroides fragilis group tested, with considerably reduced MIC90 values. The combination exhibited potent activity against other gram-negative bacteria, particularly Prevotella sp and Fusobacterium sp, as well as gram-positive pathogens such as Propionibacterium sp, Clostridium sp and anaerobic gram-positive cocci [&lt;ulink linkID="1274842" linkType="Reference"&gt;1274842&lt;/ulink&gt;], [&lt;ulink linkID="1276716" linkType="Reference"&gt;1276716&lt;/ulink&gt;], [&lt;ulink linkID="1274841" linkType="Reference"&gt;1274841&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In September 2010, preclinical data were presented at the 50th ICAAC meeting in Boston, MA. In a mouse sepsis experimental model, CXA-101 plus tazobactam (MIC = 1 mg/l) was more efficacious compared with ceftazidime (MIC = 32 mg/l) against extended-spectrum beta-lactamase (ESBL) -positive K pneumoniae 3 strain. Against ESBL- KP1 and ESBL+ KP2 strains, CXA-101 plus  tazobactam showed similar activity as ceftazidime [&lt;ulink linkID="1126508" linkType="Reference"&gt;1126508&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By June 2010, CXA-201 had demonstrated potency against P aeruginosa in vitro [&lt;ulink linkID="1111961" linkType="Reference"&gt;1111961&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In October 2012, the EMA's Pediatric Committee adopted a positive opinion on a pediatric investigation plan [&lt;ulink linkID="1331001" linkType="Reference"&gt;1331001&lt;/ulink&gt;]. In February 2017, the EMA's Pediatric Committee adopted a positive opinion on modifications to a PIP for the treatment of abdominal and gastrointestinal infections and treatment of urinary tract infections [&lt;ulink linkID="1899207" linkType="Reference"&gt;1899207&lt;/ulink&gt;]. In August 2017, the EMA's Pediatric Committee adopted a positive opinion agreeing a pediatric investigation plan for  the treatment of pneumonia [&lt;ulink linkID="1959431" linkType="Reference"&gt;1959431&lt;/ulink&gt;]. In March 2019, the EMA's Pediatric Committee adopted a positive opinion on modifications to a PIP for the treatment of intra-abdominal infections and treatment of urinary tract infections [&lt;ulink linkID="2138426" linkType="Reference"&gt;2138426&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3269">Enterobacter cloacae infection</Indication><StatusDate>2015-02-04T00:00:00.000Z</StatusDate><Source id="1631301" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="120">Escherichia coli infection</Indication><StatusDate>2019-06-25T00:00:00.000Z</StatusDate><Source id="2168816" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2994">Liver abscess</Indication><StatusDate>2019-06-25T00:00:00.000Z</StatusDate><Source id="2168816" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="120">Escherichia coli infection</Indication><StatusDate>2018-01-01T00:00:00.000Z</StatusDate><Source id="2077654" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3898">Complicated urinary tract infection</Indication><StatusDate>2016-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3334">Streptococcus anginosus infection</Indication><StatusDate>2015-02-04T00:00:00.000Z</StatusDate><Source id="1631301" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="403">Cystitis</Indication><StatusDate>2019-06-25T00:00:00.000Z</StatusDate><Source id="2168816" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3335">Streptococcus constellatus infection</Indication><StatusDate>2016-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3082">Abdominal abscess</Indication><StatusDate>2016-02-02T00:00:00.000Z</StatusDate><Source id="1736638" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3335">Streptococcus constellatus infection</Indication><StatusDate>2015-02-04T00:00:00.000Z</StatusDate><Source id="1631301" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate>2019-06-03T00:00:00.000Z</StatusDate><Source id="2158811" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="284">Pyelonephritis</Indication><StatusDate>2017-04-17T00:00:00.000Z</StatusDate><Source id="2077586" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3898">Complicated urinary tract infection</Indication><StatusDate>2016-02-22T00:00:00.000Z</StatusDate><Source id="1736638" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="137">Gram negative bacterium infection</Indication><StatusDate>2015-02-04T00:00:00.000Z</StatusDate><Source id="1631301" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="195">Klebsiella pneumoniae infection</Indication><StatusDate>2018-01-01T00:00:00.000Z</StatusDate><Source id="2077654" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="284">Pyelonephritis</Indication><StatusDate>2018-02-28T00:00:00.000Z</StatusDate><Source id="2077552" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3334">Streptococcus anginosus infection</Indication><StatusDate>2016-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3898">Complicated urinary tract infection</Indication><StatusDate>2015-02-04T00:00:00.000Z</StatusDate><Source id="1631301" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="456">Proteus mirabilis infection</Indication><StatusDate>2015-02-04T00:00:00.000Z</StatusDate><Source id="1631301" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1438">Proteus infection</Indication><StatusDate>2019-06-25T00:00:00.000Z</StatusDate><Source id="2168816" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="137">Gram negative bacterium infection</Indication><StatusDate>2017-04-17T00:00:00.000Z</StatusDate><Source id="2077586" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="312">Streptococcus infection</Indication><StatusDate>2019-06-25T00:00:00.000Z</StatusDate><Source id="2168816" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="284">Pyelonephritis</Indication><StatusDate>2017-11-15T00:00:00.000Z</StatusDate><Source id="2124690" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3898">Complicated urinary tract infection</Indication><StatusDate>2017-11-15T00:00:00.000Z</StatusDate><Source id="2124690" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3082">Abdominal abscess</Indication><StatusDate>2015-02-04T00:00:00.000Z</StatusDate><Source id="1631301" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="137">Gram negative bacterium infection</Indication><StatusDate>2018-02-28T00:00:00.000Z</StatusDate><Source id="2077552" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3082">Abdominal abscess</Indication><StatusDate>2017-03-16T00:00:00.000Z</StatusDate><Source id="2077552" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="456">Proteus mirabilis infection</Indication><StatusDate>2016-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="120">Escherichia coli infection</Indication><StatusDate>2016-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3269">Enterobacter cloacae infection</Indication><StatusDate>2016-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1434">Citrobacter infection</Indication><StatusDate>2019-06-25T00:00:00.000Z</StatusDate><Source id="2168816" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="284">Pyelonephritis</Indication><StatusDate>2019-06-25T00:00:00.000Z</StatusDate><Source id="2168816" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="280">Pseudomonas aeruginosa infection</Indication><StatusDate>2016-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1394">Bacteroides fragilis infection</Indication><StatusDate>2015-02-04T00:00:00.000Z</StatusDate><Source id="1631301" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3082">Abdominal abscess</Indication><StatusDate>2019-06-25T00:00:00.000Z</StatusDate><Source id="2168816" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="452">Peritonitis</Indication><StatusDate>2019-06-25T00:00:00.000Z</StatusDate><Source id="2168816" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="137">Gram negative bacterium infection</Indication><StatusDate>2018-01-01T00:00:00.000Z</StatusDate><Source id="2077654" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3898">Complicated urinary tract infection</Indication><StatusDate>2018-01-01T00:00:00.000Z</StatusDate><Source id="2077654" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3082">Abdominal abscess</Indication><StatusDate>2018-02-28T00:00:00.000Z</StatusDate><Source id="2077552" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3898">Complicated urinary tract infection</Indication><StatusDate>2018-02-28T00:00:00.000Z</StatusDate><Source id="2077552" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3082">Abdominal abscess</Indication><StatusDate>2016-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="137">Gram negative bacterium infection</Indication><StatusDate>2016-02-22T00:00:00.000Z</StatusDate><Source id="1736638" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3898">Complicated urinary tract infection</Indication><StatusDate>2019-06-25T00:00:00.000Z</StatusDate><Source id="2168816" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3317">Klebsiella oxytoca infection</Indication><StatusDate>2015-02-04T00:00:00.000Z</StatusDate><Source id="1631301" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="116">Enterobacter infection</Indication><StatusDate>2019-06-25T00:00:00.000Z</StatusDate><Source id="2168816" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3898">Complicated urinary tract infection</Indication><StatusDate>2017-04-17T00:00:00.000Z</StatusDate><Source id="2077586" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="280">Pseudomonas aeruginosa infection</Indication><StatusDate>2019-06-25T00:00:00.000Z</StatusDate><Source id="2168816" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="638">Klebsiella infection</Indication><StatusDate>2019-06-25T00:00:00.000Z</StatusDate><Source id="2168816" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2019">Cholecystitis</Indication><StatusDate>2019-06-25T00:00:00.000Z</StatusDate><Source id="2168816" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="456">Proteus mirabilis infection</Indication><StatusDate>2018-01-01T00:00:00.000Z</StatusDate><Source id="2077654" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3317">Klebsiella oxytoca infection</Indication><StatusDate>2016-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="195">Klebsiella pneumoniae infection</Indication><StatusDate>2016-12-31T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="280">Pseudomonas aeruginosa infection</Indication><StatusDate>2018-01-01T00:00:00.000Z</StatusDate><Source id="2077654" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3082">Abdominal abscess</Indication><StatusDate>2017-04-17T00:00:00.000Z</StatusDate><Source id="2077586" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3082">Abdominal abscess</Indication><StatusDate>2017-11-15T00:00:00.000Z</StatusDate><Source id="2124690" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="280">Pseudomonas aeruginosa infection</Indication><StatusDate>2015-02-04T00:00:00.000Z</StatusDate><Source id="1631301" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="598">Enterobacteriaceae infection</Indication><StatusDate>2019-01-08T00:00:00.000Z</StatusDate><Source id="2113240" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3082">Abdominal abscess</Indication><StatusDate>2017-04-07T00:00:00.000Z</StatusDate><Source id="1929846" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate>2019-02-05T00:00:00.000Z</StatusDate><Source id="2117044" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate>2015-01-31T00:00:00.000Z</StatusDate><Source id="1743025" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="MY">Malaysia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3082">Abdominal abscess</Indication><StatusDate>2018-04-03T00:00:00.000Z</StatusDate><Source id="2077729" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3082">Abdominal abscess</Indication><StatusDate>2018-04-03T00:00:00.000Z</StatusDate><Source id="2077729" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="TR">Turkey</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3082">Abdominal abscess</Indication><StatusDate>2018-04-03T00:00:00.000Z</StatusDate><Source id="2077729" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3082">Abdominal abscess</Indication><StatusDate>2018-04-03T00:00:00.000Z</StatusDate><Source id="2077729" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3082">Abdominal abscess</Indication><StatusDate>2016-03-24T00:00:00.000Z</StatusDate><Source id="1739793" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013295">Astellas Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="137">Gram negative bacterium infection</Indication><StatusDate>2007-11-30T00:00:00.000Z</StatusDate><Source id="1529582" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="137">Gram negative bacterium infection</Indication><StatusDate>2010-06-30T00:00:00.000Z</StatusDate><Source id="1111961" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate>2011-01-20T00:00:00.000Z</StatusDate><Source id="1162543" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate>2012-09-04T00:00:00.000Z</StatusDate><Source id="1319878" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="137">Gram negative bacterium infection</Indication><StatusDate>2007-11-30T00:00:00.000Z</StatusDate><Source id="1529582" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3898">Complicated urinary tract infection</Indication><StatusDate>2011-06-29T00:00:00.000Z</StatusDate><Source id="1204826" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="137">Gram negative bacterium infection</Indication><StatusDate>2011-10-19T00:00:00.000Z</StatusDate><Source id="1231928" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3082">Abdominal abscess</Indication><StatusDate>2011-10-31T00:00:00.000Z</StatusDate><Source id="1248352" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3082">Abdominal abscess</Indication><StatusDate>2011-10-31T00:00:00.000Z</StatusDate><Source id="1248352" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3898">Complicated urinary tract infection</Indication><StatusDate>2014-04-21T00:00:00.000Z</StatusDate><Source id="1548828" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3082">Abdominal abscess</Indication><StatusDate>2014-04-21T00:00:00.000Z</StatusDate><Source id="1548828" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="137">Gram negative bacterium infection</Indication><StatusDate>2014-04-21T00:00:00.000Z</StatusDate><Source id="1548828" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3898">Complicated urinary tract infection</Indication><StatusDate>2014-12-19T00:00:00.000Z</StatusDate><Source id="1622359" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3082">Abdominal abscess</Indication><StatusDate>2014-12-19T00:00:00.000Z</StatusDate><Source id="1622359" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="137">Gram negative bacterium infection</Indication><StatusDate>2014-12-19T00:00:00.000Z</StatusDate><Source id="1622359" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3082">Abdominal abscess</Indication><StatusDate>2014-08-22T00:00:00.000Z</StatusDate><Source id="1587108" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3898">Complicated urinary tract infection</Indication><StatusDate>2014-08-22T00:00:00.000Z</StatusDate><Source id="1587108" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3082">Abdominal abscess</Indication><StatusDate>2011-10-31T00:00:00.000Z</StatusDate><Source id="1248352" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="137">Gram negative bacterium infection</Indication><StatusDate>2015-09-30T00:00:00.000Z</StatusDate><Source id="1708728" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3898">Complicated urinary tract infection</Indication><StatusDate>2015-09-30T00:00:00.000Z</StatusDate><Source id="1708728" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3082">Abdominal abscess</Indication><StatusDate>2015-09-30T00:00:00.000Z</StatusDate><Source id="1708728" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate>2013-07-18T00:00:00.000Z</StatusDate><Source id="1454221" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3082">Abdominal abscess</Indication><StatusDate>2011-10-31T00:00:00.000Z</StatusDate><Source id="1248352" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3082">Abdominal abscess</Indication><StatusDate>2011-10-31T00:00:00.000Z</StatusDate><Source id="1248352" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3082">Abdominal abscess</Indication><StatusDate>2011-10-31T00:00:00.000Z</StatusDate><Source id="1248352" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="XE">South America</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3082">Abdominal abscess</Indication><StatusDate>2011-10-31T00:00:00.000Z</StatusDate><Source id="1248352" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3082">Abdominal abscess</Indication><StatusDate>2011-12-31T00:00:00.000Z</StatusDate><Source id="1509620" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3082">Abdominal abscess</Indication><StatusDate>2011-12-31T00:00:00.000Z</StatusDate><Source id="1509620" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate>2014-11-09T00:00:00.000Z</StatusDate><Source id="1623746" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3082">Abdominal abscess</Indication><StatusDate>2015-09-18T00:00:00.000Z</StatusDate><Source id="1699848" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3898">Complicated urinary tract infection</Indication><StatusDate>2015-09-18T00:00:00.000Z</StatusDate><Source id="1699848" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate>2014-08-31T00:00:00.000Z</StatusDate><Source id="1623745" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3082">Abdominal abscess</Indication><StatusDate>2015-01-31T00:00:00.000Z</StatusDate><Source id="1743025" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3082">Abdominal abscess</Indication><StatusDate>2016-04-20T00:00:00.000Z</StatusDate><Source id="1755020" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3082">Abdominal abscess</Indication><StatusDate>2015-01-31T00:00:00.000Z</StatusDate><Source id="1743025" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3082">Abdominal abscess</Indication><StatusDate>2016-07-31T00:00:00.000Z</StatusDate><Source id="2077552" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3082">Abdominal abscess</Indication><StatusDate>2018-02-28T00:00:00.000Z</StatusDate><Source id="2077552" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="284">Pyelonephritis</Indication><StatusDate>2016-07-31T00:00:00.000Z</StatusDate><Source id="2077552" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="284">Pyelonephritis</Indication><StatusDate>2018-02-28T00:00:00.000Z</StatusDate><Source id="2077552" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3898">Complicated urinary tract infection</Indication><StatusDate>2018-02-28T00:00:00.000Z</StatusDate><Source id="2077552" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3898">Complicated urinary tract infection</Indication><StatusDate>2016-07-31T00:00:00.000Z</StatusDate><Source id="2077552" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="137">Gram negative bacterium infection</Indication><StatusDate>2018-02-28T00:00:00.000Z</StatusDate><Source id="2077552" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="137">Gram negative bacterium infection</Indication><StatusDate>2016-07-31T00:00:00.000Z</StatusDate><Source id="2077552" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="XE">South America</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3082">Abdominal abscess</Indication><StatusDate>2015-01-31T00:00:00.000Z</StatusDate><Source id="1743025" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3082">Abdominal abscess</Indication><StatusDate>2017-03-16T00:00:00.000Z</StatusDate><Source id="2077552" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3082">Abdominal abscess</Indication><StatusDate>2015-01-31T00:00:00.000Z</StatusDate><Source id="1743025" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3082">Abdominal abscess</Indication><StatusDate>2016-08-05T00:00:00.000Z</StatusDate><Source id="2077585" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3082">Abdominal abscess</Indication><StatusDate>2017-04-17T00:00:00.000Z</StatusDate><Source id="2077586" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3898">Complicated urinary tract infection</Indication><StatusDate>2016-08-05T00:00:00.000Z</StatusDate><Source id="2077585" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3898">Complicated urinary tract infection</Indication><StatusDate>2017-04-17T00:00:00.000Z</StatusDate><Source id="2077586" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="284">Pyelonephritis</Indication><StatusDate>2017-04-17T00:00:00.000Z</StatusDate><Source id="2077586" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="284">Pyelonephritis</Indication><StatusDate>2016-08-05T00:00:00.000Z</StatusDate><Source id="2077585" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="137">Gram negative bacterium infection</Indication><StatusDate>2016-08-05T00:00:00.000Z</StatusDate><Source id="2077585" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="137">Gram negative bacterium infection</Indication><StatusDate>2017-04-17T00:00:00.000Z</StatusDate><Source id="2077586" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3898">Complicated urinary tract infection</Indication><StatusDate>2018-01-01T00:00:00.000Z</StatusDate><Source id="2077654" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="137">Gram negative bacterium infection</Indication><StatusDate>2018-01-01T00:00:00.000Z</StatusDate><Source id="2077654" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="120">Escherichia coli infection</Indication><StatusDate>2018-01-01T00:00:00.000Z</StatusDate><Source id="2077654" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="195">Klebsiella pneumoniae infection</Indication><StatusDate>2018-01-01T00:00:00.000Z</StatusDate><Source id="2077654" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="456">Proteus mirabilis infection</Indication><StatusDate>2018-01-01T00:00:00.000Z</StatusDate><Source id="2077654" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="280">Pseudomonas aeruginosa infection</Indication><StatusDate>2018-01-01T00:00:00.000Z</StatusDate><Source id="2077654" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3082">Abdominal abscess</Indication><StatusDate>2015-01-31T00:00:00.000Z</StatusDate><Source id="1743025" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3082">Abdominal abscess</Indication><StatusDate>2015-01-31T00:00:00.000Z</StatusDate><Source id="1743025" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3082">Abdominal abscess</Indication><StatusDate>2018-02-28T00:00:00.000Z</StatusDate><Source id="2009226" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3898">Complicated urinary tract infection</Indication><StatusDate>2018-02-28T00:00:00.000Z</StatusDate><Source id="2009226" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3269">Enterobacter cloacae infection</Indication><StatusDate>2014-12-12T00:00:00.000Z</StatusDate><Source id="1622503" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3317">Klebsiella oxytoca infection</Indication><StatusDate>2014-12-19T00:00:00.000Z</StatusDate><Source id="1622503" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1394">Bacteroides fragilis infection</Indication><StatusDate>2014-12-19T00:00:00.000Z</StatusDate><Source id="1622503" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3334">Streptococcus anginosus infection</Indication><StatusDate>2014-12-19T00:00:00.000Z</StatusDate><Source id="1622503" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3335">Streptococcus constellatus infection</Indication><StatusDate>2014-12-19T00:00:00.000Z</StatusDate><Source id="1622503" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3334">Streptococcus anginosus infection</Indication><StatusDate>2015-09-18T00:00:00.000Z</StatusDate><Source id="1728094" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3335">Streptococcus constellatus infection</Indication><StatusDate>2015-09-18T00:00:00.000Z</StatusDate><Source id="1728094" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3269">Enterobacter cloacae infection</Indication><StatusDate>2015-09-18T00:00:00.000Z</StatusDate><Source id="1728094" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="120">Escherichia coli infection</Indication><StatusDate>2015-09-18T00:00:00.000Z</StatusDate><Source id="1728094" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="195">Klebsiella pneumoniae infection</Indication><StatusDate>2015-09-18T00:00:00.000Z</StatusDate><Source id="1728094" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3317">Klebsiella oxytoca infection</Indication><StatusDate>2015-09-18T00:00:00.000Z</StatusDate><Source id="1728094" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="456">Proteus mirabilis infection</Indication><StatusDate>2015-09-18T00:00:00.000Z</StatusDate><Source id="1728094" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="280">Pseudomonas aeruginosa infection</Indication><StatusDate>2015-09-18T00:00:00.000Z</StatusDate><Source id="1728094" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="456">Proteus mirabilis infection</Indication><StatusDate>2014-12-19T00:00:00.000Z</StatusDate><Source id="1622503" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="280">Pseudomonas aeruginosa infection</Indication><StatusDate>2014-12-19T00:00:00.000Z</StatusDate><Source id="1622503" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate>2014-09-23T00:00:00.000Z</StatusDate><Source id="1623745" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate>2014-09-23T00:00:00.000Z</StatusDate><Source id="1623745" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3898">Complicated urinary tract infection</Indication><StatusDate>2015-10-29T00:00:00.000Z</StatusDate><Source id="1736269" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="284">Pyelonephritis</Indication><StatusDate>2015-10-29T00:00:00.000Z</StatusDate><Source id="1736269" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3082">Abdominal abscess</Indication><StatusDate>2015-10-29T00:00:00.000Z</StatusDate><Source id="1736269" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate>2019-02-05T00:00:00.000Z</StatusDate><Source id="2117044" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate>2019-06-03T00:00:00.000Z</StatusDate><Source id="2158811" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3898">Complicated urinary tract infection</Indication><StatusDate>2019-01-08T00:00:00.000Z</StatusDate><Source id="2109713" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="403">Cystitis</Indication><StatusDate>2019-01-08T00:00:00.000Z</StatusDate><Source id="2109713" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="284">Pyelonephritis</Indication><StatusDate>2019-01-08T00:00:00.000Z</StatusDate><Source id="2109713" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="452">Peritonitis</Indication><StatusDate>2019-01-08T00:00:00.000Z</StatusDate><Source id="2109713" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3082">Abdominal abscess</Indication><StatusDate>2019-01-08T00:00:00.000Z</StatusDate><Source id="2109713" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2019">Cholecystitis</Indication><StatusDate>2019-01-08T00:00:00.000Z</StatusDate><Source id="2109713" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2994">Liver abscess</Indication><StatusDate>2019-01-08T00:00:00.000Z</StatusDate><Source id="2109713" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="312">Streptococcus infection</Indication><StatusDate>2019-01-08T00:00:00.000Z</StatusDate><Source id="2113240" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="120">Escherichia coli infection</Indication><StatusDate>2019-01-08T00:00:00.000Z</StatusDate><Source id="2113240" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1434">Citrobacter infection</Indication><StatusDate>2019-01-08T00:00:00.000Z</StatusDate><Source id="2113240" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="638">Klebsiella infection</Indication><StatusDate>2019-01-08T00:00:00.000Z</StatusDate><Source id="2113240" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="116">Enterobacter infection</Indication><StatusDate>2019-01-08T00:00:00.000Z</StatusDate><Source id="2113240" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1438">Proteus infection</Indication><StatusDate>2019-01-08T00:00:00.000Z</StatusDate><Source id="2113240" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="280">Pseudomonas aeruginosa infection</Indication><StatusDate>2019-01-08T00:00:00.000Z</StatusDate><Source id="2113240" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1046343">Calixa Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="137">Gram negative bacterium infection</Indication><StatusDate>2007-11-30T00:00:00.000Z</StatusDate><Source id="1529582" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1046343">Calixa Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="137">Gram negative bacterium infection</Indication><StatusDate>2009-09-16T00:00:00.000Z</StatusDate><Source id="1069268" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21697">Cubist Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="137">Gram negative bacterium infection</Indication><StatusDate>2009-12-16T00:00:00.000Z</StatusDate><Source id="1064636" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="21697">Cubist Pharmaceuticals Inc</OwnerCompany><Country id="US">US</Country><Indication id="3898">Complicated urinary tract infection</Indication><AwardedIndication>For Complicated urinary tract infections</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2013-05-07T00:00:00.000Z</MileStoneDate><Source id="1416427" type="PR"/></Row><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="21697">Cubist Pharmaceuticals Inc</OwnerCompany><Country id="US">US</Country><Indication id="1815">Bacterial pneumonia</Indication><AwardedIndication>For hospital-acquired bacterial pneumonia (HABP) / ventilator-associated bacterial pneumonia (VABP)</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2013-05-07T00:00:00.000Z</MileStoneDate><Source id="1416427" type="PR"/></Row><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="21697">Cubist Pharmaceuticals Inc</OwnerCompany><Country id="US">US</Country><Indication id="3082">Abdominal abscess</Indication><AwardedIndication>For complicated intra-abdominal infections</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2013-02-28T00:00:00.000Z</MileStoneDate><Source id="1387641" type="PR"/></Row><Row><RegulatoryDesignation id="11">Priority Review</RegulatoryDesignation><OwnerCompany id="18077">Merck &amp; Co Inc</OwnerCompany><Country id="US">US</Country><Indication id="1815">Bacterial pneumonia</Indication><AwardedIndication>Treatment of adult patients with nosocomial pneumonia, including ventilator-associated bacterial pneumonia  (VABP) caused by certain susceptible Gram-negative microorganisms</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2019-02-05T00:00:00.000Z</MileStoneDate><Source id="2117044" type="PR"/></Row><Row><RegulatoryDesignation id="12">Qualified Infectious Disease Product</RegulatoryDesignation><OwnerCompany id="21697">Cubist Pharmaceuticals Inc</OwnerCompany><Country id="US">US</Country><Indication id="3898">Complicated urinary tract infection</Indication><AwardedIndication>Complicated urinary tract infections (cUTI)</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2013-02-28T00:00:00.000Z</MileStoneDate><Source id="1387641" type="PR"/></Row><Row><RegulatoryDesignation id="12">Qualified Infectious Disease Product</RegulatoryDesignation><OwnerCompany id="21697">Cubist Pharmaceuticals Inc</OwnerCompany><Country id="US">US</Country><Indication id="1815">Bacterial pneumonia</Indication><AwardedIndication>Hospital-acquired bacterial pneumonia (HABP)/Ventilator-associated bacterial pneumonia (VABP)</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2013-02-28T00:00:00.000Z</MileStoneDate><Source id="1387641" type="PR"/></Row><Row><RegulatoryDesignation id="12">Qualified Infectious Disease Product</RegulatoryDesignation><OwnerCompany id="21697">Cubist Pharmaceuticals Inc</OwnerCompany><Country id="US">US</Country><Indication id="3082">Abdominal abscess</Indication><AwardedIndication>Complicated intra-abdominal infections</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2012-12-06T00:00:00.000Z</MileStoneDate><Source id="1348383" type="PR"/></Row><Row><RegulatoryDesignation id="12">Qualified Infectious Disease Product</RegulatoryDesignation><OwnerCompany id="21697">Cubist Pharmaceuticals Inc</OwnerCompany><Country id="US">US</Country><Indication id="1815">Bacterial pneumonia</Indication><AwardedIndication>Hospital-acquired bacterial pneumonia (HABP)/Ventilator-associated bacterial pneumonia (VABP)</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="3">Filed</DesignationApplicationStatus><MileStoneDate>2012-10-19T00:00:00.000Z</MileStoneDate><Source id="1333041" type="PR"/></Row><Row><RegulatoryDesignation id="12">Qualified Infectious Disease Product</RegulatoryDesignation><OwnerCompany id="21697">Cubist Pharmaceuticals Inc</OwnerCompany><Country id="US">US</Country><Indication id="3898">Complicated urinary tract infection</Indication><AwardedIndication>Complicated urinary tract infections (cUTI)</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="3">Filed</DesignationApplicationStatus><MileStoneDate>2012-10-19T00:00:00.000Z</MileStoneDate><Source id="1333041" type="PR"/></Row><Row><RegulatoryDesignation id="12">Qualified Infectious Disease Product</RegulatoryDesignation><OwnerCompany id="21697">Cubist Pharmaceuticals Inc</OwnerCompany><Country id="US">US</Country><Indication id="3082">Abdominal abscess</Indication><AwardedIndication>Complicated intra-abdominal infections</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="3">Filed</DesignationApplicationStatus><MileStoneDate>2012-10-19T00:00:00.000Z</MileStoneDate><Source id="1333041" type="PR"/></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-00196"><Name>Beta lactamase</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2168816" linkType="reference" linkID="2168816"&gt;2168816&lt;/ulink&gt;]							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1013295">Astellas Pharma Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="18077">Merck &amp; Co Inc</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>C[C@@]1([C@@H](N2[C@H](S1(=O)=O)CC2=O)C(=O)O)Cn3ccnn3</Smiles><Smiles>C[C@@]1([C@@H](N2[C@H](S1(=O)=O)CC2=O)C(=O)O)Cn3ccnn3.CC(C)(C(=O)O)O/N=C(/c1nc(sn1)N)\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[n+]4cc(c(n4C)N)NC(=O)NCCN)C(=O)O.OS(=O)(=O)[O-]</Smiles><Smiles>CC(C)(C(=O)O)O/N=C(/c1nc(sn1)N)\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[n+]4cc(c(n4C)N)NC(=O)NCCN)C(=O)O</Smiles><Smiles>C[C@@]1([C@@H](N2[C@H](S1(=O)=O)CC2=O)C(=O)[O-])Cn3ccnn3.CC(C)(C(=O)O)O/N=C(/c1nc(sn1)N)\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[n+]4cc(c(n4C)N)NC(=O)NCCN)C(=O)O.OS(=O)(=O)[O-].[Na+]</Smiles></StructureSmiles><Deals><Deal id="121886" title="Calixa to develop Astellas Pharma's cephalosprin derivatives worldwide        "/><Deal id="178940" title="CXA-101 (ceftolozane) cephalosporin antibiotic for pseudomonal infections worldwide ex-Asia-Pacific"/></Deals><PatentFamilies><PatentFamily id="1245054" number="WO-2004039814" title="Cephem compounds"/><PatentFamily id="2491747" number="WO-2013036783" title="Methods for treating intrapulmonary infections"/><PatentFamily id="2558267" number="US-08476425" title="Tazobactam arginine compositions"/><PatentFamily id="2709237" number="WO-2014052799" title="Tazobactam arginine antibiotic compositions"/><PatentFamily id="2798189" number="WO-2014144295" title="Ceftolozane antibiotic compositions"/><PatentFamily id="2840570" number="WO-2015048217" title="Solid forms of ceftolozane"/><PatentFamily id="2904861" number="WO-2015035376" title="Treating infections with ceftolozane/tazobactam in subjects having impaired renal function"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>3</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>5</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Astellas Pharma Inc" id="1013295"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Merck &amp; Co Inc" id="18077"/><CountAsOwner>7</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>7</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Wakunaga Pharmaceutical Co Ltd" id="20786"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>Y</hasSWOTs></Drug></drugRecordsOutput>